CH637643A5 - Acylated 2-benzimidazole derivatives - Google Patents

Abstract

Acylated 2-benzimidazole derivatives of the formula <IMAGE> in which R denotes an optionally esterified or amidated carboxyl group or an optionally etherified or esterified hydroxymethyl group, R1 represents an aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic or heterocyclic-aliphatic radical, R2 represents hydrogen or an aliphatic radical, and Ph represents a 1,2-phenylene group containing the radical R1-C(=O)-, have antiallergic properties and can be used as antiallergic pharmaceutical active compounds. They were prepared, for example, by reacting an appropriate 1,2-phenylenediamine, which is substituted by the acyl radical of the formula R1-C(=O) and can optionally also contain further substituents, or an acid addition salt thereof, e.g. its hydrochloride, with an acid of the formula R-COOH or a suitable reactive derivative thereof.

Description

The invention relates to benzimidazole-2 derivatives of the formula

"/ N \

R] _ - C - Ph j; C-R (I),

N I

R2

wherein R is an optionally esterified or amidated carboxy group or an optionally etherified or esterified hydroxymethyl group, Ri represents an aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic or heterocyclic-aliphatic radical, R2 represents hydrogen or an aliphatic radical, and Ph represents a 1,2-phenylene group containing the radical Ri-C (= 0), with the proviso that Ri has at least 2 carbon atoms if pH is otherwise unsubstituted, R2 is ethyl and R is acetoxymethyl, and salts of such compounds with salt-forming Properties.

In connection with the present description, organic radicals and compounds denoted by “lower” contain in particular up to and with 7, preferably up to and with 4 carbon atoms. The exception is based on J. Chem. Soc. (C) 1969, pp. 70-74.

In esterified carboxy and etherified hydroxymethyl R, the etherified hydroxy group means, for example, a hydroxy group etherified by an aliphatic or araliphatic radical, such as an optionally substituted aliphatic or araliphatic hydrocarbon radical, e.g. corresponding lower alkoxy or phenyl-lower alkoxy. Substitutes from Niederkoxy include Hydroxy, lower alkoxy and / or halogen, where one or more substituents may be present.

In amidated carboxy, the amino group means, for example, optionally monosubstituted by hydroxy or by aliphatic radicals, in particular optionally substituted aliphatic hydrocarbon radicals, mono- or disubstituted amino, where such radicals can be mono- or diva-lent, such as optionally monosubstituted by hydroxy or by corresponding lower alkyl or Lower alkylene mono- or disubstituted amino.

In esterified hydroxymethyl R, the esterified hydroxy group means, for example, hydroxy esterified with a carboxylic acid, such as an aliphatic or aromatic carboxylic acid, e.g. Corresponding lower alkanoyloxy or benzoyloxy optionally substituted by lower alkyl, lower alkoxy and / or halogen. Lower alkanoyloxy is e.g. Acetoxy, propionyloxy, butyryloxy, isobutyryloxy, valeroyloxy, Ca-proyloxy or pivaloyloxy.

Aliphatic, cycloaliphatic, armoatic and araliphatic radicals Rj and R2 are primarily optionally substituted aliphatic, cycloaliphatic, aromatic or araliphatic hydrocarbon radicals, such as corresponding lower alkyl, lower alkenyl, cycloalkyl, phenyl, naphthyl or phenyl-lower alkyl. Substituents are e.g. Hydroxy, lower alkoxy, lower alkyl or phenylthio, lower alkyl or phenylsulfinyl, or lower alkyl or phenylsulfonyl, in particular of lower alkyl R 1 and lower alkyl R 2, furthermore lower alkyl, lower alkoxy and / or halogen, in particular of phenyl or phenyl lower alkyl R |. Heterocyclyl in a heterocyclic or heterocyclic-aliphatic radical Ri is primarily monocyclic heterocyclyl aromatic character

5

10th

15

20th

25th

30th

35

40

45

50

55

60

65

637 643

4th

ters with a heteroatom, such as oxygen, sulfur or nitrogen, as a ring member, such as furyl, thienyl or pyridyl. In a heterocyclic aliphatic radical Ri, the aliphatic part is e.g. a corresponding aliphatic hydrocarbon radical, in particular lower alkyl.

In addition to the rest of the formula Ri-C (= O), 1,2-phenylene can also, among other things. be substituted one or more times by lower alkyl, lower alkoxy, hydroxy and / or halogen.

Lower alkoxy means e.g. Methoxy, ethoxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, tert-butyl-oxy, n-pentyloxy or n-hexyloxy.

Phenyl lower alkoxy is e.g. Benzyloxy or 1- or 2-phenylethoxy.

Hydroxy, lower alkoxy or di-lower alkylamino lower alkoxy is in particular 2- and / or 3-hydroxy-lower alkoxy, e.g. 2-hydroxyethoxy, 3-hydroxypropyloxy or 2,3-dihydro-xy-propyloxy, as well as 2- or 3-lower alkoxy-lower alkoxy, e.g.

2-methoxyethoxy, 2-ethoxyethoxy or 2-methoxypropyloxy, or di-lower alkylamino lower alkoxy, e.g. Dimethylamino or diethylaminoethoxy.

Lower alkyl is e.g. Methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl or n-hep-tyl.

Halogen is especially halogen with atomic numbers up to 35, i.e. Fluorine, chlorine or bromine.

Lower alkylene is e.g. 1,4-butylene, 1,5-pentylene or 1,6-hexylene.

Lower alkenyl is e.g. Vinyl, 1-methyl-vinyl, 1-ethyl-vinyl, allyl, 2- or 3-methyl-allyl or 3,3-dimethylallyl.

Cycloalkyl preferably contains 3 to 8 ring atoms and is e.g. Cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.

Lower alkylthio is e.g. Methylthio or ethylthio, while lower alkylsulfinyl and lower alkylsulfonyl e.g. Mean methylsulfinyl, ethylsulfinyl, methylsulfonyl or ethylsulfonyl.

Lower alkyl substituted by lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl is e.g. Methyltio- or ethylthiomethyl, 1- or 2-methylthio- or 1- or 2-ethylthioethyl, or 2- or 3-methylthio- or 2- or

3-ethylthiopropyl, methylsulfinyl or ethylsulfinylmethyl,

1- or 2-methylsulfinyl- or 1- or 2-ethylsulfinyl-ethyl, or 2- or 3-methylsulfinyl- or 2- or 3-ethylsulfinylpro-pyl, or methylsulfonyl or ethylsulfonylmethyl, 1- or

2-methylsulfonyl- or 1- or 2-ethylsulfonyl-ethyl, or 2- or 3-methylsulfonyl or 2- or 3-ethylsulfonylpropyl. Lower alkyl substituted by phenylthio, phenylsulfinyl or phenylsulfonyl is e.g. Phenylthio-, Phenylsulfinyl- or Phenylsulfonylmethyl, or 1- or 2-PhenyIthio-, 1- or 2-PhenyIsulfinyl-, or 1- or 2-Phenylsulfonyläthyl.

Phenyl lower alkyl is e.g. Benzyl, 1- or 2-phenylethyI or 1-, 2- or 3-phenylpropyl.

Furyl is e.g. 2-furyl, and thienyl e.g. 2-thienyl, while pyridyl can be 2-, 3- or 4-pyridyl.

Furyl-lower alkyl, thienyl-lower alkyl and pyridyl-lower alkyl are in particular appropriately substituted methyl radicals, such as furfuryl, 2-thienyl or picolyl, e.g. 2- or 4-pyridylmethyl.

Salts are those of compounds of formula I, wherein R is carboxy, with bases; such salts are, in particular, pharmaceutically usable, non-toxic salts with bases such as alkali metal or alkaline earth metal, e.g. Sodium, potassium, magnesium or calcium salts, also ammonium salts with ammonia or amines such as lower alkyl or hydroxy lower alkyl amines, e.g. Trimethylamine, triethylamine or di- or tri- (2-hydroxyethyl) amine.

The new compounds show valuable pharmacological properties. In particular, they exhibit anti-allergic

Effects on e.g. on the rat in doses of about 0.03 to about 10 mg / kg for intravenous and in doses of about 1 to about 100 mg / kg for oral administration in the passive cutaneous anaphylaxis test (PCA reaction), which is analogous to that of Goose and Blair, Immunology, vol. 16, p. 749 (1969) can be detected, the passive cutaneous anaphylaxis according to the method described by Ovary, Progr. Allergy, vol. 5, p. 459 (1958) Process is generated. The antiallergic, in particular the degranulation-inhibiting effect can also be carried out in an in vitro experiment on the basis of the histamine release from rat peritoneal cells in the dose range from about 0.1 to about 100 jig / ml in the case of immunologically induced release (whereby rats infected with Nippostrongylus brasiliensis, for example, are used ) and from about 1.0 to about 100 jig / ml in the case of chemically induced release (this being effected, for example, with a polymer of N-4-methoxy-phenylethyl-N-methyl-amine). The compounds of the present invention are therefore useful as inhibitors of allergic reactions, e.g. in the treatment and prophylaxis of diseases such as asthma, both extrinsic and intrinsic asthma, or other allergic diseases such as allergic rhinitis, e.g. Hay fever, conjunctivitis, or allergic dermatitis, e.g. Urticaria or eczema can be used.

The invention relates in particular to compounds of the formula I in which R is esterified carboxy or etherified hydroxymethyl, as the amino group, amino, hydroxyamino, lower alkylamino, amidylene alkylamino or lower alkoxy, lower alkoxy, hydroxy-lower alkoxy, hydroxy-lower alkoxy, lower alkoxy lower alkoxy or di-lower-alkoxy lower alkoxy or ether-containing hydroxymethyl esterified hydroxyl group lower alkanoyloxy or esterified hydroxymethyl containing benzoyloxy optionally substituted by lower alkyl, lower alkoxy and / or halogen, R 1 optionally substituted by lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, phenylthio, phenylsulfinyl or phenylsulfonyl, lower alkyl, lower alkenyl, cycloxyalkyl, lower alkenyl, cycloalkyl or halogen substituted phenyl or phenyl-lower alkyl, furyl, thienyl or pyridyl, or furyl-lower alkyl, thienylnie deralkyl or pyridyl-lower alkyl means R2 represents hydrogen or lower alkyl, and Ph stands for the rest of the formula Ri-C (= O) - containing and optionally substituted by lower alkyl, lower alkoxy, hydroxy and / or halogen 1,2-phenylene, with the proviso that Ri has at least 2 carbon atoms if Ph is otherwise unsubstituted, R2 is ethyl and R is acetoxymethyl, and salts, in particular pharmaceutically acceptable salts, of compounds of the formula I in which R is carboxy.

The invention relates primarily to compounds of the formula

0 / • N.

, II / V \

R'-C 1- II; c-R '(Ia),

1 *\, * /

wherein R 'on the one hand primarily for carboxy or further as etherified hydroxy group lower alkoxy with up to and with 4 carbon atoms, e.g. Methoxy or ethoxy, having esterified carboxy or amidated carboxy having amino or aminoamino groups, or on the other hand primarily hydroxymethyl or further as etherified hydroxy group lower alkoxy having up to 4 carbon atoms, e.g. Methoxy or ethoxy, or di-lower alkyl

5

10th

15

20th

25th

30th

35

40

45

50

55

60

65

5

637 643

amino-lower alkoxy with up to 7 carbon atoms, e.g. Dimethylaminoethoxy, etherified hydroxymethyl or lower alkanoyloxy with up to 7 carbon atoms, e.g. Is acetoxy, having esterified hydroxymethyl, and wherein Ri 'is especially lower alkyl of up to 7 carbon atoms, e.g. Methyl, ethyl, n-propyl, n-butyl, tert-butyl, n-pentyl, n-hexyl or n-heptyl, furthermore lower alkoxy-lower alkyl, lower alkylthionie-deralkyl, lower alkylsulfinyl-lower alkyl, phenylthione-lower alkyl or phenylsulfinyl-lower alkyl, in which the lower alkyl radicals contain up to 4 carbon atoms included, e.g. Methoxy, methylthio, methylsulfinyl, phenylthio or phenylsulfinylmethyl, 2-methoxy, 2-methylthio, 2-methylsulfinyl,

2-phenylthio- or 2-phenylsulfinylethyl, or 3-methoxy-,

3-methylthio, 3-methylsulfinyl, 3-phenylthio or 3-phenylsulfinyl-propyl, cycloalkyl with up to and with 6 ring carbon atoms, e.g. Cyclopropyl or cyclohexyl, phenyl, furyl or pyridyl, e.g. 3- or 4-pyridyl, represents R2 'especially for hydrogen, further for lower alkyl with up to 4 carbon atoms, e.g. Methyl, and R3 is hydrogen, lower alkyl with up to and with carbon atoms, e.g. Methyl, lower alkoxy of up to 4 carbon atoms, e.g. Methoxy, hydroxy or halogen with atomic numbers up to and including 35, e.g. Chlorine means, where the rest of the formula Ri '- (= O) - and the group R3, if it is other than hydrogen, can take any of those suitable for substitution, preferably the 5- and 6-position of the benzimidazole ring, with the proviso that Ri 'has at least 2 carbon atoms when R3 is hydrogen, R2' ethyl and R 'acetoxymethyl, and salts, in particular pharmaceutically usable salts of those compounds of the formula I in which R' is carboxy, with bases.

The invention relates primarily to compounds of the formula Ia, in which R 'is either carboxy or hydroxymethyl, and in which Ri' is lower alkyl with up to 7, e.g. with up to and with 4 carbon atoms, e.g. Methyl,

Represents ethyl, n-propyl, isopropyl or n-butyl, R2 'represents hydrogen and R3 is hydrogen or lower alkyl of up to 4 carbon atoms, e.g. Represents methyl, the radical Ri'-C (= O) - the 5- and a lower alkyl radical R3 taking the 6-position of the benzimidazole ring, and the salts, in particular pharmaceutically usable salts of compounds in which R 'is carboxy, with bases.

The invention relates in particular to the compounds of the formula I mentioned in the examples.

The compounds of the formula I can be prepared, for example, by using a corresponding 1,2-phenylenediamine which is substituted by the acyl radical of the formula Ri-C (= O) and may optionally contain further substituents, or an acid addition salt thereof, e.g. its hydrochloride, with an acid of the formula R-COOH or a suitable reactive derivative, preferably esters such as lower alkyl esters, amide or anhydride such as acid halide thereof, e.g. with the optionally etherified glycolic acid, and, if desired, converting a compound obtainable according to the process into another compound of the formula I and / or converting a free salt-forming compound obtained according to the process into a salt or a salt obtained according to the process into the free compound or into a transferred other salt.

If necessary, the reaction is carried out in the presence of a solvent or diluent such as a lower alkanol, e.g. of methanol or ethanol, and / or with heating to about 50 ° C to about 160 ° C, e.g. to about 110 ° C to about 140 ° C.

The 1,2-phenylenediamines to be used as starting materials can, for example, by conventional reduction, such as reaction with a chemical reducing agent, such as

Sodium dithionite, or with suitably activated hydrogen, such as by a noble metal catalyst in a basic environment, e.g. can be obtained by Raney nickel in methanol or ethanol, catalytically activated hydrogen, the corresponding 5 1,2-nitraniline compound. In a modification of this method, this 1,2-nitraniline intermediate can also be treated with the acid mentioned above, e.g. with glycolic or oxalic acid, or with a suitable derivative thereof, e.g. with glycolic acid or a chloroalkalic acid-10 deralkyl ester, and then the nitro group, e.g. with hydrogen in the presence of Raney nickel.

The reduction of the nitro group can, however, also be effected by intramolecular disproportionation by using a corresponding disubstituted 1,2-nitraniline of the formula Ri-C (= O) -Ph (N02) -NR2-ethyl of the acid treatment, e.g. exposure to a Lewis acid such as zinc chloride in a carboxylic anhydride, e.g. Acetic anhydride, undergoes ring closure to the corresponding compound of For-20 mei I, wherein R is hydroxymethyl esterified with a carboxylic acid and R2 is different from hydrogen.

The 1,2-nitraniline compounds to be used for the preparation of the starting materials can, unless they are known, e.g. starting from the corresponding chlorobenzenes of the formula H-PhH-Cl by preparing them in a conventional manner, e.g. by reaction with a compound of the formula RpCOHal or (RiCCXhO acylated in the presence of aluminum trichloride, the compound of the formula Ri-CO-PhH-Cl thus obtained is nitrated with nitric acid / sulfuric acid and the chloronitro compound of the formula Ri-CO-Ph (Cl) thus obtainable -NC> 2 with ammonia or an amine of the formula R2NH2.

A compound of the formula I 35 obtainable according to the process can be converted into another compound of the formula I in a manner known per se.

Thus, in a compound of the formula I in which R is carboxy, this can be converted into an esterified carboxy group by esterification processes known per se. 40 For example, by treatment with a suitable diazo compound, such as a diazo lower alkane, with a suitable N, N-di-lower alkyl formamide acetal, e.g. N, N-dimethylformamide diethyl acetal or N, N-dimethylformamide methosulfate, or an oxonium salt, such as with a Trinie-45 deralkyloxonium tetrafluoroborate or hexafluorophosphate, with a carbonate or pyrocarbonate, e.g. with diethyl (pyro) carbonate, or with organic sulfite or phosphite, such as di-lower alkyl sulfite or tri-lower alkyl phosphite, in the presence of a suitable acidic agent, such as p-toluenesulfonic acid, or with an alcohol in the presence of a suitable condensing agent, such as a dehydrating agent, e.g. Dicyclohexylcarbodiimide, or, to form a hydroxy lower alkyl group, with an epoxy lower alkane, e.g. Ethylene oxide, esterify. Furthermore, a compound of For-55 mei I, in which a free carboxyl group R in salt form, e.g. is in the alkali metal, such as sodium salt form, with a reactive ester of an alcohol, e.g. with a strong acid, such as a corresponding halide, e.g. Chloride, bromide or iodide, or disubstituted sulfate, or a compound of formula I wherein a free carboxyl group R is in an anhydride form, preferably as a halocarbonyl, e.g. Chlorocarbonyl group, which is e.g. by treating a compound of formula I, wherein R is carboxy, with a halogenating agent, e.g. Can form thionyl chloride, 65, with an acid-binding base, and thus arrive at a compound of formula I, wherein R is esterified carboxy. Any substituents present in an esterification reagent may be functional

637 643

6

modified form and then in a compound of formula I wherein R e.g. stands for substituted lower alkoxycar-bonyl, in which substituents are present in a functionally modified form, are released. For example, as an esterification reagent, use the 2,3-epoxy-propyl chloride and subsequently hydrolyze a 2,3-epoxy-propyloxy group R in the resulting ester to the desired 2,3-dihydroxy-propyloxy group.

In a compound of formula I, wherein R is esterified carboxy, e.g. p-nitro- or 2,4-dinitrophenoxy- or -benzyloxycarbonyl, this can be by transesterification, e.g. by treatment with an alcohol, if necessary in the presence of a suitable transesterification catalyst such as an optionally substituted alkali metal, e.g. Sodium or potassium alkanolate, can be converted to another esterified carboxy group.

In a compound of the formula I obtained, in which R represents free, anhydridized or esterified carboxy, this can furthermore be converted in a manner known per se into optionally substituted carbamyl. Thus one can use a compound of formula I wherein a carboxyl group R is in an anhydride form, especially as a halocarbonyl, e.g. Treat chlorocarbonyl group, or is in esterified form, with ammonia, hydroxylamine or a primary or secondary amine and thus arrive at compounds of the formula I in which R represents optionally substituted carbamyl. Furthermore, the ammonium salt or an amine salt of a compound of the formula I in which R is carboxy can be converted by dehydration with a suitable dehydrating agent, such as sulfuric acid, into a compound of the formula I in which R is optionally substituted carbamyl.

The compounds mentioned, in which R is carboxy in halide form, can be prepared from compounds of the formula I in which R is carboxy by treatment with a thionyl halide, such as thionyl chloride. If R2 is hydrogen, these can form compounds of the formula

P ^ Cü-Pi h-COR,

dimerize. Such an intermediate can e.g. by treatment with a suitable alcoholate such as an alkali metal e.g. Sodium or potassium alcoholate, or with an alcohol in the presence of a mineral acid, e.g. Hydrogen chloride, or with ammonia, hydroxylamine or a primary or secondary amine, can be converted into a compound of the formula I in which R represents esterified carboxy or optionally substituted carbamyl.

In a compound of formula I, an esterified carboxyl group R can be converted into the free carboxyl group in a conventional manner, e.g. by hydrolysis, usually in an alkaline medium, such as by treatment with water in the presence of an alkali metal or alkaline earth metal hydroxide, e.g. Sodium hydroxide.

In a compound of formula I in which R2 is hydrogen, this can e.g. by treatment with a reactive ester of a corresponding alcohol, such as a halide, in the presence of a base, e.g. an alkali metal alcoholate, are replaced by an aliphatic radical.

A carboxy group R which is optionally in halide or salt form can also be reduced to hydroxymethyl by reaction with a borohydride or with hydrogen in the presence of a hydrogenation catalyst. For the reduction of an optionally in salt form, e.g. as the alkali metal, such as sodium salt, carboxy group present, a borane, e.g. Diboran or the borantetrahydrofuran complex. Halocarbonyl groups, such as chlorocarbonyl, are preferably reduced with hydrogen in the presence of palladium, preferably on a support, such as barium sulfate, and if necessary a sulfur-containing cocatalyst, e.g. of thiourea.

Furthermore, in a compound of formula I in which R is hydroxymethyl, this can be carried out in a conventional manner, e.g. 15 by reaction with an etherifying agent, convert into an etherified hydroxymethyl group. Etherifying agents are, for example, reactive esters of corresponding alcohols, for example their esters with inorganic acids, such as hydrochloric, bromine or hydroiodic acid or sulfuric acid, or with organic sulfonic acids, e.g. with methane,

Benzene-, p-bromobenzene- or p-toluenesulfonic acid, furthermore epoxides derived from corresponding 1,2-diols. The reaction with the etherifying agents mentioned can take place in a customary manner, for example in the presence of an alkali metal hydride or alcoholate, e.g. of sodium hydride or sodium methoxide, or by treating the compound to be etherified as a salt, e.g. Sodium salt. Furthermore, in a compound of formula I in which R is hydroxymethyl, it can be esterified in a conventional manner, e.g. by direct esterification with an appropriate carboxylic acid in the presence of a mineral acid, e.g. of hydrochloric acid or sulfuric acid, or by reaction with a reactive derivative, e.g. an anhydride, such as the anhydride or chloride, or an ester, such as lower alkyl or p-nitrophenyl, 35 2,3-dinitrophenyl ester, the carboxylic acid, if necessary in the presence of an acidic or especially basic condensing agent, when reacting with an acid anhydride, e.g. of pyridine, and when reacted with an ester, e.g. an alkali metal such as sodium or potassium alcohol 4o tes, into an esterified hydroxymethyl group R. The etherification or esterification of a hydroxymethyl group can, however, also be carried out in such a way that this is first carried out in a conventional manner, e.g. with phosphorus tribromide or thionyl chloride, converted into a halomethyl group and then 45 with an alkali metal, e.g. the sodium alcoholate, the corresponding alcohol, or an alkali metal, e.g. the sodium salt of the corresponding carboxylic acid.

If appropriate, esterified hydroxymethyl groups R can be further oxidized to carboxy groups and etherified hydroxymethyl groups to esterified carboxy groups. The oxidation can be carried out in a manner known per se, e.g. by reaction with an oxidizing heavy metal compound, starting from hydroxymethyl, preferably with an oxidizing compound containing chromium VI-55 or manganese VII, e.g. with chromium trioxide or in particular potassium permanganate, starting from etherified hydroxymethyl R, also with a manganese VI-containing compound, such as manganese dioxide. It is preferably carried out in the presence of a suitable solvent or diluent, e.g. of acetone or pyridine, or a preferably aqueous mixture thereof, if necessary with cooling or heating, e.g. in a temperature range from about 0 ° C to about 80 ° C.

65

Free compounds of the formula I obtained, in which R is carboxy, can be converted into salts in a manner known per se, i.a. by treating with a base or

7

637 643

with a suitable salt of a carboxylic acid, usually in the presence of a solvent or diluent.

Salts obtained can be converted into the free compounds in a manner known per se, e.g. by treating with an acidic reagent such as a mineral acid.

The compounds, including their salts, can also be obtained in the form of their hydrates or include the solvent used for the crystallization.

As a result of the close relationship between the new compounds in free form and in the form of their salts, in the preceding and the following, the free compounds or their salts are also to be understood as meaningful and appropriate, if appropriate, the corresponding salts or free compounds.

The pharmaceutical preparations which contain compounds of the formula I or pharmaceutically acceptable salts thereof are those for enteral, such as oral, nasal or rectal, and also parenteral or topical administration to warm-blooded animals which contain the pharmacological active ingredient alone or together with a pharmaceutical applicable carrier material included. The dosage of the active ingredient depends on the warm-blooded species, the age and the individual condition, as well as on the mode of administration.

The pharmaceutical preparations contain e.g. to about 95%, preferably from about 5% to about 90% of the active ingredient. Pharmaceutical preparations according to the invention are e.g. those in unit dosage forms, such as coated tablets, tablets, capsules or suppositories, and ampoules, furthermore inhalation preparations, furthermore topical and local pharmaceutical preparations (e.g. for insufflation).

The pharmaceutical preparations are made in a manner known per se, e.g. produced by conventional mixing, granulating, coating, solution or lyophilization processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active ingredient with solid carriers, optionally granulating a mixture obtained, and processing the mixture or granules, if desired or necessary, into tablets or Dragées cores after adding suitable auxiliaries .

Suitable carriers are in particular fillers such as sugar, e.g. Lactose, sucrose, mannitol or sorbitol, cellulose preparations and / or calcium phosphates, e.g. Tricalçium phosphate or calcium hydrogen phosphate, further binders such as starch paste and use e.g. of corn, wheat, rice or potato starch, gelatin, tragacanth, methyl cellulose and / or polyvinylpyrrolidone, and / or, if desired, disintegrants, such as the above-mentioned starches, furthermore carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar, Al- gic acid or a salt thereof, such as sodium alginate. Aids are primarily flow regulators and lubricants, e.g. Silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and / or polyethylene glycol. Dragée kernels are provided with suitable, possibly gastric juice-resistant coatings, whereby one of the things Concentrated sugar solutions, which optionally contain arabic gum, talc, polyvinylpyrrolidone, polyethylene glycol and / or titanium dioxide, lacquer solutions in suitable organic solvents or solvent mixtures or, for the production of gastric juice-resistant coatings, solutions of suitable cellulose preparations, such as acetyl cellulose phthalate or hydroxypropylmethyl cellulose phthalate. Dyes or pigments, e.g. for identification or for labeling different doses of active ingredient.

Other pharmaceutical preparations that can be used orally are plug-in capsules made of gelatin, and soft, closed capsules made of gelatin and a plasticizer, such as glycerol or sor-

bitol. The capsules can contain the active ingredient in the form of granules, e.g. in a mixture with fillers, such as lactose, binders, such as starches, and / or lubricants, such as talc or magnesium stearate, and optionally stabilizers. In soft capsules, the active ingredient is preferably dissolved or suspended in suitable liquids, such as fatty oils, paraffin oil or liquid polyethylene glycols, stabilizers also being able to be added.

As rectally applicable pharmaceutical preparations, e.g. Suppositories into consideration, which consist of a combination of the active ingredient with a suppository base. Suitable suppository bases are e.g. natural or synthetic triglycerides, paraffin hydrocarbons, poly-ethylene glycols or higher alkanols. Gelatin rectal capsules can also be used, which contain a combination of the active ingredient with a base material; as basic materials come e.g. liquid triglycerides, poly-ethylene glycols or paraffin hydrocarbons in question.

For parenteral administration, primarily aqueous solutions of an active ingredient in water-soluble form, e.g. a water-soluble salt, further suspensions of the active ingredient, such as corresponding oily injection suspensions, using suitable lipophilic solvents or vehicles, such as fatty oils, e.g. Sesame oil, or synthetic fatty acid esters, e.g. Ethyl oleate or triglycerides, or aqueous injection suspensions containing viscosity-increasing substances, e.g. Contain sodium carboxymethyl cellulose, sorbitol and / or dextran and optionally by stabilizers.

Inhalation preparations for the treatment of the respiratory tract by nasal or buccal administration are e.g. Aerosols or sprays, which can distribute the pharmacological active ingredient in the form of a powder or in the form of drops of a solution or suspension. In addition to the active ingredient, preparations with powder-distributing properties usually contain a liquid propellant with a boiling point below room temperature, and, if desired, carriers, such as liquid or solid nonionic or anionic surface-active agents and / or solid diluents. Preparations in which the pharmacological active ingredient is in solution contain, in addition to this, a suitable propellant and, if necessary, an additional solvent and / or a stabilizer. Instead of the propellant gas, compressed air can also be used, which can be generated as required by means of a suitable compression and expansion device.

Pharmaceutical preparations for topical and local use are e.g. for the treatment of the skin lotions and creams containing a liquid or semi-solid oil-in-water or water-in-oil emulsion, and ointments (preferably containing a preservative), for the treatment of the eyes eye drops which are the Active compound contained in aqueous or oily solution and eye ointments, which are preferably made in sterile form, for the treatment of nose powders, aerosols and sprays (similar to those described above for the treatment of the respiratory tract), as well as coarse powder, which can be inhaled quickly the nostrils are administered, and nasal drops which contain the active compound in aqueous or oily solution, or for local treatment of the mouth, lozenges which contain the active compound in a mass generally formed from sugar and gum arabic or tragacanth, to which flavorings have been added can, as well as pastilles, the active substance in an inert mass, for made of gelatin and glycerin or sugar and gum arabic.

The daily dose, which is administered to a warm-blooded animal of approximately 70 kg, is, depending on the form of application, from approximately 2 mg to approximately 7000 mg.

5

10th

15

20th

25th

30th

35

40

45

50

55

60

65

637 643

8th

The following examples illustrate the invention described above; however, they are not intended to limit their scope in any way. Temperatures are given in degrees Celsius.

example 1

A mixture of 44.6 g of crude 4,5-diamino-2-methyl-butyrophenone and 23 g of glycolic acid is heated to an internal temperature of 130 ° under a nitrogen atmosphere and kept at this temperature for 2-1 / 2 hours. The brown-black reaction mass is cooled to room temperature and in about 300 ml of 2-n. Hydrochloric acid dissolved; the solution containing brown flakes is mixed with an activated carbon preparation and filtered through a diatomaceous earth preparation (Hyflo). The clear brown filtrate is adjusted to pH 9 by adding an aqueous concentrated sodium hydroxide solution. It is cooled in an ice bath and the crystalline precipitate is filtered off, washed with water and dried at 100 mm / Hg and 50 ° for 6 hours. The product is dissolved in 100 ml of hot ethanol, mixed with an activated carbon preparation and filtered, and the filtrate is diluted with 100 ml of water. The 5-butyryl-6-methyl-benzimidazole - 2-methanol obtainable in this way is filtered off and washed with water and diethyl ether, mp 176-178 °.

The starting material can be obtained as follows:

The yellow suspension of 900 ml of 3-chlorotoluene and 367.5 g of aluminum chloride (finely pulverized) is mixed with 266 g of butyric acid chloride within one hour. Hydrogen chloride gas develops during the dropping; the reaction is exothermic (the temperature is allowed to rise to 70 °) and the aluminum chloride dissolves. After the addition of the butyric acid chloride has ended, the reaction mixture is kept at 70 ° until the evolution of gas ceases (about 45 minutes), then cools to 50 ° and pours onto 2500 g of ice.

Two identical batches are taken together and extracted with ethyl acetate; the organic extract is twice with 2-n. Hydrochloric acid, once with a saturated aqueous sodium chloride solution, twice with a 2-n. aqueous sodium carbonate solution and washed once with a saturated aqueous sodium chloride solution, dried and evaporated. The brown, oily residue obtainable in this way is distilled; the mixture of 4-chloro-2-methyl-butyrophenone and 2-chloro-4-methyl-butyrophenone is obtained at 160-163 ° / 14 mm Hg.

Concentrated sulfuric acid (1275 ml), cooled to -20 ° to -25 ° using a carbon dioxide / chloroform mixture, is added dropwise with 285.5 g of the mixture of 4-chloro-2-methyl-butyro within 10 minutes with good stirring -phenon and 2-chloro-4-methyl-butyrophenone added. The resulting solution is treated at -20 ° to -25 ° within 30 minutes with a mixture of 240 ml of concentrated sulfuric acid and 75 ml of 100% nitric acid (d: 1.52) and then continued for 15 minutes, while maintaining the temperature can be raised to —15 °. Pour onto 8000 ml of ice water; the precipitated oil is extracted with chloroform. The organic extract is washed once with an aqueous sodium hydrogen carbonate solution and once with water, dried over sodium sulfate and evaporated. The residue is dissolved in twice the amount of hot methanol and left to stand for 16 hours. The crystalline precipitate is filtered off, washed with cold water and dried at 100 mm Hg and room temperature for 18 hours. This gives 4-chloro-2-methyl-5-nitro-butyrophenone, which melts at 71-72 °.

A solution of 120.7 g of 4-chloro-2-methyl-5-nitro-butyro-phenone in 250 ml of dimethyl sulfoxide is heated to a temperature of 95-100 °, a strong ammonia stream being passed through during the heating. The mixture is treated with ammonia gas at a temperature of 95-100 ° for a further 18 hours, then cooled and poured onto about 5000 ml of an ice / water mixture. The product begins to precipitate as a resin, but crystallizes on stirring. It is filtered; the coarse product is triturated and washed with water, then dissolved in about 1000 ml of ethyl acetate. The solution is dried over sodium sulfate and evaporated. The residue is dissolved in 245 ml of hot benzene, mixed with an activated carbon preparation and filtered; the filtrate is diluted with 490 ml of petroleum ether and the crystalline 4-amino-2-methyl-5-nitrobutyrophenone is filtered off, mp 90-92 °.

A solution of 66.6 g of 4-amino-2-methyl-5-nitrobutyro-phenone in 600 ml of dioxane and 150 ml of water is heated to reflux with stirring and added dropwise within 15 minutes with a solution of 240 g of sodium dithionite in 1050 ml Water added. The reaction mixture is further boiled for 15 minutes, then treated dropwise with 150 ml of concentrated hydrochloric acid within 30 minutes, a pH of 3 being reached and quite a lot of sulfur dioxide being formed. The organic solvent is evaporated; the residue is made alkaline with an aqueous sodium hydroxide solution and extracted with chloroform. The organic extract is washed twice with water, dried over sodium sulfate and evaporated. The 4,5-diamino-2-methy-butyrophenone thus available, mp 84-87 °, is used without further purification.

The conversion of 4-chloro-2-methyl-5-nitro-butyro-phenone into 4,5-diamino-2-methyl-butyrophenone can also be carried out as follows, it being possible to start from a crude isomer mixture.

24.5 g of crude chloromethyl-nitro-butyrophenone (about 75% strength 4-chloro-2-methyl-5-nitro-butyrophenone) are dissolved in 300 ml of ethanol and transferred to an autoclave. Then 50 g of ammonia are pressed on and heated to 100 ° for 12 hours. It is evaporated to dryness under reduced pressure, 200 ml of 2N nitric acid are added, the mixture is heated at 80-90 ° for one hour, cooled to 10-15 ° by adding ice and suction filtered. The residue is dissolved in methylene chloride, dried over sodium sulfate and, finally, with the addition of cyclohexane, evaporated. The crystalline 4-amino-2-methyl-5-nitro-butyrophenone is filtered off and washed with petroleum ether. It melts at 92-95 °.

66.7 g of 4-amino-2-methyl-5-nitro-butyrophenone are dissolved in 900 ml of methanol, mixed with 7 g of Raney nickel and hydrogenated at 20-25 ° under normal pressure. After 19.6 liters of hydrogen have been taken up, the hydrogenation is terminated, the catalyst is filtered off, 100 ml of concentrated hydrochloric acid are added and the methanol is removed under reduced pressure. The now crystalline 4,5-diamino-2-methyl-butyrophenone hydrochloride is filtered off, washed with ethanol / ether and dried. It melts over 160 ° with partial decomposition.

Example 2

A suspension of 2.95 g of 5-butyryl-6-methyl-benzimi-dazol-2-methanol in 180 ml of acetone is diluted with 140 ml of water, with solution being added while stirring. 2.95 g of potassium permanganate are added to this at room temperature and stirring is continued for one hour at room temperature, the violet color of the oxidizing agent disappearing and the brown-black sludge of the manganese dioxide separating out. The acetone is drawn off under reduced pressure, the suspension obtained is filtered with the aid of a diatomaceous earth preparation (Hyflo) and washed with water. The filtrate is adjusted to pH 3 to 3.5 with acetic acid; the flaky precipitate formed is filtered off, washed with water and dried at 35 °. The so available

5

10th

15

20th

25th

30th

35

40

45

50

55

60

65

9

637 643

5-Butyryl-6-methyl-benzimidazole-2-carboxylic acid melts depending on the rate of heating and with decomposition at 127-137 °.

The sodium salt of 5-butyryl-6-methyl-benzimidazole-2-carboxylic acid can be obtained by lyophilizing a solution of the free acid in an aqueous solution of the equivalent amount of sodium hydroxide. It melts at 275 °.

Example 3

A mixture of 9.8 g of 5-amino-2-methyl-4-methylamino-butyrophenone and 4.15 g of glycolic acid is heated in an oil bath at 130 °. After 150 minutes, the reaction product together with the product of a second batch of 3 g of 5-amino-2-methyl-4-methylamino-butyrophenone and 1.27 g of glycolic acid, in 300 ml of 2-n. Hydrochloric acid taken up and filtered. The filtrate is made alkaline; the extracted oil is extracted with three portions of ethyl acetate,

washes the organic extract twice with water, dry-kneads, filters and evaporates. The brown, oily residue crystallizes spontaneously and is recrystallized from ethyl acetate. The 5-butyryl-1, 6-dimethyl-benzimi-dazol-2-methanol obtainable in this way melts at 141.5-142.5 °.

The starting material can be produced as follows:

A mixture of 24.1 g of 4-chloro-2-methyl-5-nitro-butyro-phenone and 250 ml of a 33% solution of methylamine in ethanol is left to stand at room temperature; the crystalline starting material slowly dissolves, with a yellow color. The reaction is weakly exothermic; it is therefore cooled with a water bath to prevent excessive escape of methylamine. Complete solution occurs after 20 minutes, then a precipitate begins to precipitate. The mixture is left to stand at room temperature for 16 hours and then evaporated to dryness under reduced pressure. The residue is mixed with diethyl ether (about 1000 ml), ice and sodium carbonate, shaken and the organic layer separated. This is washed twice with water and the aqueous solution is washed back with diethyl ether. The combined organic solutions are dried over sodium sulfate, filtered and evaporated to a volume of about 300 ml, then diluted with 100 ml of petroleum ether and cooled. The yellow, crystalline 2-methyl-4-methylamino-5-nitro-butyrophenone precipitates, is filtered off, washed with petroleum ether and air-dried, mp 107-108 °.

A solution of 4.7 g of 2-methyl-4-methylamino-5-nitro-butyrophenone in 40 ml of dioxane is diluted with water and heated to reflux, then within 10 minutes with a solution of 16 g of sodium dithionite in 70 ml of water treated, the yellow color of the reaction mixture fades. The mixture is refluxed for a further 15 minutes and the pH is adjusted by adding about 30 ml of 6-n. Hydrochloric acid to 3 and boil again under reflux for 15 minutes, during which time the sulfur dioxide escapes. The pH of the reaction mixture is adjusted to 2, boiled again under reflux for about 5 minutes and the dioxane is then evaporated off under reduced pressure. The hydrochloride of 5-amino-2-methyl-4-methylamino-butyrophenone precipitates out of the remaining solution; the suspension is cooled, made alkaline with concentrated aqueous sodium hydroxide solution and extracted with chloroform. The organic extract is washed twice with water, dried, filtered and evaporated. The 5-amino-2-methyl-4-methylamino-butyrophenone melts at 126-128 °.

The conversion of 4-chloro-2-methyl-5-nitro-butyro-phenone into 5-amino-2-methyl-4-methylamino-butyrophenone can also be carried out as follows, it also being possible to start from a crude isomer mixture.

241 g of crude chloromethyl nitrobutyrophenone (about 75% of 4-chloro-2-methyl-5-nitro-butyrophenone) are suspended in 1200 ml of ethanol and mixed with 1200 ml of 33-methylamine solution, followed by an exothermic reaction Dissolution takes place. The mixture is left to stand for 2 days, evaporated to dryness under reduced pressure, mixed with 600 ml of 2N hydrochloric acid and heated to 80-90 ° for 1 hour. The mixture is cooled to about 15 ° by adding ice, the crystalline precipitate is filtered off, washed with water, taken up in methylene chloride, dried over sodium sulfate, steamed under reduced pressure, finally with the addition of cyclohexane and petroleum ether (boiling range 60-80 ° ), the methylene chloride, cools and sucks the 2-methyl-4-methylamino-5-nitro-butyrophenone of mp. 105-107 °.

59.1 g of 2-methyl-4-methylamino-5-nitro-butyrophenone are dissolved in 1000 ml of methanol with 6 g of Raney nickel and hydrogenated at 20-25 ° under normal pressure. After 16.8 liters of hydrogen have been taken up, the hydrogenation is stopped, gently heated to dissolve the precipitate, filtered off from the catalyst, mixed with 50 ml of concentrated hydrochloric acid, cooled to 3 ° and suction filtered. The 5-amino-2-methyl-4-methylamino-butyrophenone hydrochloride of mp over 180 ° (dec.) Is obtained.

Example 4

A solution of 1.23 g of 5-butyryl-1, 6-dimethyl-benzimidazole-2-methanol in 75 ml of acetone and 25 ml of water is treated with stirring with 1.2 g of potassium permanganate, which is added all at once. After an initially weakly exothermic reaction, the manganese dioxide begins to precipitate after 30 minutes. After four hours, a small amount of isopropanol is added to the reaction mixture, then the organic solvent is evaporated under reduced pressure. The remaining aqueous suspension is filtered through a diatomaceous earth preparation (Hyflo). The cloudy extract is discarded. The last traces of chloroform are removed from the aqueous phase under reduced pressure and then treated with an activated carbon preparation and filtered. The filtrate is adjusted to pH 3-4 with acetic acid, whereupon the 5-butyryl-1,6-dimethyl-benzimidazole-2-carboxylic acid begins to precipitate in the form of fine needles. The mixture is cooled, the precipitate is filtered off, washed with water and diethyl ether and dried at room temperature under high vacuum, mp above 110 ° (dec.). The sodium salt melts at 275-280 ° (from aqueous acetone).

Example 5

A mixture of 2.9 g of 3,4-diamino-valerophenone and 1.5 g of glycolic acid is heated under a nitrogen atmosphere at 130 ° for 2 hours. After cooling, the reaction product in 2-n. Hydrochloric acid added; an activated carbon preparation is added, the mixture is filtered through a diatomaceous earth preparation (Hyflo) and the filtrate is made alkaline by adding concentrated aqueous sodium hydroxide solution. The crystalline precipitate is filtered off, washed with water and diethyl ether and dried. The 5 (6) -valeryl-benzimidazole-2-methanol obtainable in this way melts at 134-136 °.

The starting material can be produced as follows:

A mixture of 346 ml of chlorobenzene and 120 g of valeryl chloride is mixed in portions with 147 g of aluminum chloride at room temperature over the course of 1 hour, heating up to 70 ° at the same time. The mixture is stirred for a further hour at this temperature, then cooled to 25 ° and the dark red reaction mixture is poured onto 1000 g of ice. Concentrated hydrochloric acid is added and the mixture is then extracted with ethyl acetate. The organic extract is with 2-n. Washed hydrochloric acid, filtered through a diatomaceous earth preparation (Hyflo) and again with 2-n. Hydrochloric acid, twice with water, with 2-n. aqueous sodium carbonate solution and with

5

10th

15

20th

25th

30th

35

40

45

50

55

60

65

637 643

10th

Washed water. It is dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue is distilled; the 4-chloro-valerophenone is obtained at 155-156 ° / 14 mm Hg .; the product crystallizes and melts at 28-30 °.

While cooling with an ice-sodium chloride mixture, 50 ml of concentrated sulfuric acid are mixed with 9.9 g of 4-chloro-valerophenone while stirring. With a weakly exothermic reaction, most of the product dissolves and a yellow suspension is formed which, with vigorous stirring and at a temperature of from -10 ° to -5 °, is mixed with a mixture of 20 ml of concentrated sulfuric acid and within 10 minutes 10.4 ml of concentrated nitric acid (d = 1.52) is added. After a reaction time of five minutes, the mixture is poured onto ice and the aqueous mixture is extracted with chloroform. The organic extract is washed once with an aqueous sodium carbonate solution and with water, dried over sodium sulfate and filtered through silica gel. The 4-chloro-3-nitro-valerophenone is obtained as an oily residue after evaporation of the filtrate.

Gaseous ammonia is passed through at room temperature through a solution of 18.1 g of 4-chloro-3-nitro-valero-phenone in 40 ml of dimethyl sulfoxide. A yellow color appears immediately and the solution heats up to over 40 °. After 105 minutes (final temperature: 32 °), the reaction mixture is heated to 70 ° with further introduction of ammonia, held at this temperature for two hours, then heated at 95 ° for a further two hours. After cooling, the mixture is poured onto about 400 ml of water, then acidified with concentrated hydrochloric acid and, after a few minutes, made alkaline again with concentrated aqueous ammonia solution. The yellow crystalline precipitate is filtered off; the moist crystals are taken up in ethyl acetate, the solution is dried over sodium sulfate, filtered and evaporated. The crystalline residue is dissolved in hot benzene, mixed with silica gel and filtered. The still brown filtrate is diluted with petroleum ether, treated again with silica gel in the heat and filtered. The filtrate is diluted with petroleum ether; the 4-amino-3-nitro - valerophenone crystallizes out and is filtered off, mp 115-117 °.

A suspension of 3.9 g of 4-amino-3-nitro-valerophenone in 35 ml of dioxane and 9 ml of water is heated to reflux, and 14 g of sodium dithionite in 60 ml of water are added to the resulting solution over the course of 10 minutes. You continue to cook under reflux for 15 minutes,

then drips 6-n. Hydrochloric acid up to pH 3, whereby some sulfur dioxide escapes. The pH is adjusted to 2, the mixture is left to react for a few minutes and the organic solvent is then removed under reduced pressure. The remaining aqueous suspension is made alkaline in the cold and extracted with 5 portions of 50 ml of chloroform. The combined organic extracts are washed twice with water, dried, filtered and evaporated. The 3,4-diamino-valerophenone is obtained in the form of brown crystals, mp 106-107 °.

Example 6

A solution of 1.15 g of 5 (6) -valeryl-benzimidazole-2-methanol in 75 ml of acetone and 55 ml of water is mixed with 1.15 g of potassium permanganate, which is added all at once, and stirred for one hour at room temperature . After 5 minutes the manganese dioxide begins to precipitate and after 30 minutes the violet color has disappeared. The acetone is evaporated off under reduced pressure; the remaining mixture is filtered through a diatomaceous earth preparation (Hyflo) and the filter residue is washed with water. The filtrate is acidified to pH 4 with acetic acid; the resulting

Precipitate is filtered off, washed with water and dried at room temperature. The 5 (6) -valeryl-benzimidazole-2-carboxylic acid thus obtainable melts at 145 ° (with decomposition).

Example 7

In an analogous manner to that described in Examples 1 to 3, i.a. the following connections are made:

5-acetyl-6-methyl-benzimidazole-2-carboxylic acid;

6-methyl-5-propionyl-benzimidazole-2-carboxylic acid; 5-butyryl-6-methoxy-benzimidazole-2-carboxylic acid; 5-butyryl-6-chloro-benzimidazole-2-carboxylic acid; 5-cyclopropylcarbonyl-6-methyl-benzimidazole-2-carboxylic acid; 5-cyclohexylcarbonyl-6-methyl-benzimidazole-2-carboxylic acid;

5- (4-methoxy-butyryl) -6-methyl-benzimidazole-2-carboxylic acid;

6-methyl-5- (4-methylthio-butyryl) benzimidazole-2-carboxylic acid; 6-methyl-5- (4-methylsulfinyl-butyryl) benzimidazole-2-carbon

acid;

6-methyl-5- (4-phenylthio-butyryl) benzimidazole-2-carboxylic acid; 6-methyl-5- (4-phenylsulfinyl-butyryl) benzimidazole-2-carboxylic acid;

and

5-Butyryl-6-methyl-benzimidazole-2-carboxylic acid methyl ester. Example 8

59.1 g of 2-methyl-4-methylamino-5-nitro-butyrphenone are dissolved in 1000 ml of methanol, mixed with 6 g of Raney nickel and hydrogenated at 20-25 ° under normal pressure. After 17.2 liters of hydrogen have been taken up, the hydrogenation is stopped, the reaction mixture is gently warmed and a solution of 17.1 g of glycolic acid in 30 ml of methanol is added under nitrogen. The catalyst is filtered off, evaporated to dryness under reduced pressure and heated to 130 ° for 3 hours. After cooling, it is dissolved in 2N hydrochloric acid, washed with ethyl acetate, made alkaline and extracted with methylene chloride. The extract is washed twice with water, concentrated to 100 ml, mixed with ethyl acetate and the methylene chloride is stripped off completely. The precipitated 5-butyryl-1,6-dimethyl-benzimi-dazol-2-methanol of mp. 141.5-142.5 ° is suctioned off and dried in vacuo.

The starting material can be produced as follows:

241 g of chloromethyl-nitro-butyrophenone (about 75% strength of 4-chloro-2-methyl-5-nitro-butyrophenone) are suspended in 1200 ml of ethanol, mixed with 1200 ml of 33% strength methylamine solution and gently warmed. When the exothermic reaction begins, the mixture is cooled slightly and then left to stand at room temperature for 2 days. It is evaporated to dryness under reduced pressure, 600 ml of 2N hydrochloric acid are added, the mixture is heated at 80-90 ° for 1 hour, cooled to about 15 ° by the addition of ice and suction filtered. It is washed with water, dissolved in methylene chloride, dried over sodium sulfate, concentrated under reduced pressure, cyclohexane is added, the methylene chloride is completely stripped off, filtered off with suction and dried in vacuo. The 2-methyl-4-methylamino-5-nitro-butyrophenone melts at 105-107 °.

Example 9

41.5 g of 4-amino-2-methyl-5-nitro-valerophenone, dissolved in 500 ml of methanol, are mixed with 4 g of Raney nickel and hydrogenated at normal pressure until 11.6 liters of hydrogen are taken up. A solution of 26.6 g of glycolic acid in 100 ml of methanol is added to the crude hydrogenation solution which contains the 5-methyl-4-valeryl-1,2-phenylene-diamine which is formed, and a catalyst is filtered off under nitrogen. The methanol is removed under reduced pressure and the residue is heated to 130 ° for 90 minutes, 400 ml of 2N hydrochloric acid are added after cooling, the mixture is stirred for one hour with ei5

10th

15

20th

25th

30th

35

40

45

50

55

60

65

11

637 643

added to a filter aid and filtered through diatomaceous earth. The filtrate is first washed with concentrated sodium hydroxide solution,

then brought to pH = 9 with 4N sodium carbonate solution and cooled, the 6-methyl-5-valeryl-benzimidazole-2-methanol precipitating. It is filtered off, washed with 200 ml of ethyl acetate and dried under reduced pressure. The product melts at 169-171 °. From the ethyl acetate used for washing, further product of mp. 168-170 ° can be obtained by concentration to about 50 ml.

The starting material can be produced as follows:

302 g of valeroyl chloride are added dropwise within 120 minutes to a stirred suspension of 367 g of aluminum tri-chloride in 900 ml of m-chlorotoluene. The reaction temperature should not exceed 45 °; if necessary, cooling with ice water. You let it stir for a few hours

pour on 4000 g of ice and extract with ethyl acetate. The combined extracts are washed twice with water, dried over sodium sulfate and evaporated under reduced pressure, lastly at 80 °. The residue is distilled under reduced pressure, an isomer mixture containing about 50% of 4-chloro-2-methylvalerophenone passing over at 150 ° and 12 mm / Hg.

130 ml of sulfuric acid cooled to -23 ° are added dropwise at -25 ° to -20 ° first with the isomer mixture containing about 50% of 4-chloro-2-methylvalerophenone and then with a mixture of 24 ml of sulfuric acid and 7.5 ml of nitric acid of density 1.52. The reaction is complete after about 20 minutes. It is poured onto 600 g of ice, filtered off, taken up in chloroform, washed successively with saturated sodium carbonate solution and twice with water, dried over sodium sulfate and evaporated to dryness. The evaporation residue is taken up in 40 ml of methanol. On cooling, an isomer mixture containing about 50% of 4-chloro-2-methyl-5-nitro-valerophenone crystallized out. It is suctioned off and washed with cold methanol.

In a heated to 95-100 ° solution of 38 g of the approximately 50% 4-chloro-2-methyl-5-nitro-valerophenone containing isomer mixture in 240 ml of dimethyl sulfoxide, ammonia is introduced for about 14 hours until an intense yellow color. The mixture is allowed to cool, poured onto 2000 g of ice, acidified with concentrated hydrochloric acid, made alkaline with sodium hydroxide solution, suction filtered, washed with water, dried at 40 °, suspended in boiling cyclohexane and suction filtered again. Chromatographically pure 4-amino-2-methyl-5-nitro-valerophenone with a melting point of 108-112 ° is obtained.

Example 10

A solution of 9.85 g of 6-methyl-5-valeryl-benzimidazole - 2-methanol in a mixture of 350 ml of acetone and 80 ml of water is mixed with stirring at room temperature with 9.5 g of potassium permanganate. The reaction that starts soon can be controlled, if necessary, by external cooling with ice water. After 2 hours, the mixture is filtered through diatomaceous earth, the acetone is stripped off under reduced pressure and the solution is filtered clearly, if necessary with the aid of a filter aid. The filtrate is acidified with acetic acid and the fine precipitate which separates is filtered off with suction, dissolved in 100 ml of n-sodium hydroxide solution, reset to pH 7.5 and filtered again clearly. The filtrate is acidified, the 6-methyl-5-valeryl-benzimi-dazol-2-carboxylic acid which immediately precipitates is washed with water and dried in vacuo. The product begins to melt at 132 ° with decomposition.

Example 11

A solution of 30.1 g of 4-amino-3-nitro-butyrophenone in 300 ml of methanol is mixed with 3 g of Raney nickel and at

Hydrogenated 20-35 ° under normal pressure. After taking up 9.87 liters of hydrogen, a solution of 21.9 g of glycolic acid in 50 ml of methanol is added under nitrogen, the catalyst is filtered off and the mixture is evaporated to dryness. The evaporation residue is heated to 130 ° for 90 minutes, dissolved after cooling with 600 ml of 2N hydrochloric acid, filtered to pH 8 and extracted with a total of about 2000 ml of methylene chloride. The combined extracts are concentrated to about 200 ml under reduced pressure. The precipitate is filtered off, suspended in 200 ml of ethyl acetate, suction filtered again and dried in vacuo. The 5 (6) -butyryl-benzimidazole-2-methanol of mp. 141-143 ° is obtained.

The starting material can be produced as follows:

A solution of 18.3 g of 4-chloro-butyrophenone in 100 ml of -20 ° sulfuric acid is added within 5 minutes at -20 to -15 ° with a mixture of 40 ml of sulfuric acid and 21 ml of fuming nitric acid, all in solution goes. The mixture is stirred at -15 ° to -10 ° for 45 minutes, poured onto 1000 g of ice, filtered off, washed with water, taken up in chloroform, washed with saturated sodium bicarbonate solution and twice with water, dried over sodium sulfate, filtered and evaporated to Dry it up. The evaporation residue is digested with 25 ml of methanol. The 4-chloro-3-nitro-butyrophenone of mp 52-54 ° is obtained.

50 g of ammonia are injected into an autoclave onto a solution of 22.8 g of 4-chloro-3-nitro-butyrophenone in 300 ml of ethanol. It is heated to 100 ° for 10 hours, after cooling to room temperature, evaporated to dryness under reduced pressure, heated to 80-90 ° for 1 hour with 200 ml of 2N hydrochloric acid, cooled to 15 ° by adding ice, suction filtered and washed with water . The filter cake is taken up in 1000 ml of methylene chloride, dried over sodium sulfate, concentrated, petroleum ether (boiling range 60-80 °) is added and the methylene chloride is completely evaporated. The crystalline 4-amino-3-nitro-butyro-phenone is filtered off and dried in vacuo. It melts at 128-129 °.

Example 12

A solution of 6.5 g of 5 (6) -butyryl-benzimidazole-2-methanol in 300 ml of acetone and 60 ml of water is mixed with 0.5 g of potassium permanganate, briefly cooled in a water bath and stirred for 3 hours at room temperature. The mixture is then filtered through diatomaceous earth, the acetone removed under reduced pressure, extracted twice with chloroform, filtered through diatomaceous earth, if necessary with a filter aid, and acidified with 2N-acetic acid. The precipitated 5 (6) - butyryl-benzimidazole-2-carboxylic acid is filtered off, washed with water and dried in vacuo. It melts at over 150 °.

Example 13

A solution of 35.5 g of 4-methylamino-3-nitro-aceto-phenone in 500 ml of methanol is mixed with 4 g of Raney nickel and hydrogenated at 30-35 °. After the absorption of 12.7 liters of hydrogen, a solution of 27.3 g of glycolic acid in 100 ml of methanol is added under nitrogen, the catalyst is filtered off and the mixture is evaporated to dryness under reduced pressure. The residue is heated to 130 ° under nitrogen for 90 minutes. After cooling to room temperature, it is dissolved in 300 ml of 2N hydrochloric acid and, if necessary, filtered with filter aid. The filtrate is brought to pH = 7-8 with concentrated sodium hydroxide solution and finally with sodium carbonate solution and extracted with methylene chloride. The methylene chloride phase is shaken out 5 times with methylene chloride. The combined methylene chloride phases are concentrated to 300 ml and the precipitated 5-acetyl-l-methyl-benzimi-

5

10th

IS

20th

25th

30th

35

40

45

50

55

60

65

637 643

12

Aspirated 2-methanol at mp 178-179 ° suctioned off. By concentrating the mother liquor to 100 ml, additional product of mp 176-177 ° can be obtained.

The starting material can be produced as follows:

A solution of 15.5 g of 4-chloroacetophenone in 100 ml of -20 ° sulfuric acid is added within 2 minutes with a mixture of 40 ml of sulfuric acid and 21 ml of fuming nitric acid, stirred at -25 ° to -20 ° for 1 hour Poured 600 g of ice, filtered off the precipitate, washed with water and taken up in chloroform. The chloroform solution is washed with saturated sodium bicarbonate solution and twice with water, dried over sodium sulfate, filtered and evaporated to dryness. The evaporation residue is recrystallized from 50 ml of methanol. 4-Chloro-3-nitro-acetophenone of mp 92-95 ° is obtained.

39.9 g of 4-chloro-3-nitro-acetophenone are suspended in 200 ml of ethanol, mixed with 200 ml of a 33% strength aqueous methylamine solution, stirred until crystallization begins and then left to stand for a few days with occasional shaking. It is evaporated to dryness under reduced pressure, poured with 200 ml of 2N hydrochloric acid, warmed to 30 °, allowed to cool, made alkaline and extracted with methylene chloride. The extract is washed with water, dried over sodium sulfate, filtered and evaporated. The remaining 4-methylamino-3-nitro-acetophenone is recrystallized from cyclohexane. It melts at 118-120 °.

Example 14

In a manner analogous to that described in Example 10, 4.1 g of 5-acetyl-1-methyl-benzimidazole-2-methanol with 4 g of potassium permanganate can be converted into 5-acetyl-1-methyl-benzimidazole-2-carbonic acid from the mp 135 ° can be oxidized.

here. The extracts are washed successively with 2N hydrochloric acid, water, 2N sodium carbonate solution and twice with water, dried over sodium sulfate and, finally at 70 ° in a water jet vacuum, strongly concentrated. The residue is distilled. 5 The 2,4-dichlorobutyrophenon has the Kpi2 = 135-141 °.

A mixture of 24 ml of sulfuric acid and 7.5 ml of fuming nitric acid is added to a solution of 32.6 g of 2,4-dichlorobutyrophenone in 130 ml of sulfuric acid, cooled to −23 °, within 10 minutes at −25 ° to −20 ° added, stirred for 15 minutes at -25 ° to -20 °, poured onto ice and extracted with chloroform. The extracts are washed successively with water, sodium bicarbonate solution and twice with water, dried over sodium sulfate and evaporated. The 2,4-dichloro-5-nitro-butyrophenone with a melting point of 145-50 ° can be further converted crude by dissolving 26.2 g of the same in 50 ml of ethanol and 150 ml of a 33% solution cooled to 8 ° aqueous methylamino solution are added dropwise. The mixture is stirred for 2 hours at 5 ° to 8 °,

evaporates to dryness under reduced pressure, 20 is added with 150 ml of 2N hydrochloric acid and heated to 80-90 ° for a few minutes. Then it is cooled to 10 ° with ice, suction filtered, washed with water, dissolved in methylene chloride, dried over sodium sulfate, concentrated under reduced pressure, mixed with cyclohexane, cooled to 15 ° and the 2-chloro-4-25 is suctioned off -methylamino-5-nitro-butyrophenone. It melts at 95-97 ° after drying.

Example 18

In an analogous manner to that described in Example 10, 2.7 g of 5-butyryl-6-chloro-l-methyl-benzimidazole-2-methanol are mixed with 2.5 g of potassium permanganate to give 5-butyryl-6-chloro-l-methyl- -benzimidazole-2-carboxylic acid, mp. 90 ° (dec.), oxidized.

Example 15

In an analogous manner to that described in Example 13, starting from 34.2 g of 4-chloro-3-nitro-butyrophenone, 100 ml of 33% aqueous methylamine solution and 20 g of glycolic acid via 4-methylamino-3-nitro-butyrophenone from the mp. 71 ° the 5-butyryl-l-methyl-benzimidazole-2-methanol of mp. 152-154 °.

Example 16

In an analogous manner to that described in Example 10, 18.5 g of 5-butyryl-1-methyl-benzimidazole-2-methanol with 18.5 g of potassium permanganate to give 5-butyryl-1-methyl-benzimidazole-2 - carboxylic acid, mp. over 90 ° (dec.).

Example 17

A solution of 18.8 g of 2-chloro-4-methylamino-5-nitro - butyrophenone in 190 ml of methanol is mixed with 2 g of Raney nickel and hydrogenated at 20-27 ° under normal pressure. After 5 liters of hydrogen have been taken up, a solution of 11.4 g of glycolic acid in 50 ml of methanol is added under nitrogen, the catalyst is filtered off and the mixture is evaporated to dryness under reduced pressure. The residue is heated to 130 ° under nitrogen for 1 hour and, after cooling, triturated with methanol, whereupon crystallization occurs. The crystals are cooled, suction filtered and washed with cold methanol. 5-Butyryl-6-chloro-l-methyl-benzimidazole-2-methanol of mp. 183-185 ° is obtained.

The starting material can be produced as follows:

293 g of aluminum tri-chloride are added to 685 ml of m-dichlorobenzene, heated to 70 ° and 213 g of butyryl chloride are added dropwise with stirring at 70-90 ° over the course of 30 minutes. The mixture is stirred at 80-90 ° for 2 hours, poured onto 3000 g of ice after cooling and extracted with ethyl acetate.

35 Example 19

15.7 g of 2-methyl-4-methylamino-5-nitro-valerophenone in 180 ml of methanol are mixed with 2 g of Raney nickel and hydrogenated at normal pressure and 20-35 °. After taking up 4.2 l of hydrogen, a solution of 9.12 g of glycolic acid in 50 ml of methanol is added under nitrogen, the catalyst is filtered off and the mixture is evaporated to dryness. The residue is heated to 130 ° under nitrogen for 90 minutes and, after cooling, is dissolved in 100 ml of 2N hydrochloric acid. It is filtered over diatomaceous earth, made alkaline, extracted with methylene chloride ex-45, washed twice with water, dried over sodium sulfate and evaporated. The residue is recrystallized from 100 ml of ethyl acetate. 1, 6-Dimethyl-5-vaIeryl-benzimidazole-2-methanol of mp 125 ° is obtained.

The starting material can be produced as follows:

17.5 g of crude mononitro-4-chloro-2-methyl-butyrophenone (about 50% of 4-chloro-2-methyl-5-nitro-butyrophenone) are poured over with 150 ml of a 33% aqueous methylamine solution and after Allow to stand for 4 hours at room temperature and evaporated to dryness. The residue is dissolved in 100 ml of warm 2N hydrochloric acid, the solution is made alkaline with sodium carbonate solution and extracted three times with methylene chloride. The extracts are washed twice with water, dried over sodium sulfate and evaporated. The remaining 60 crude 2-methyl-4-methylamino-5-nitro-valerophenone is recrystallized from cyclohexane / petroleum ether and then melts at 72-77 °.

Example 20

65 In a manner analogous to that described in Example 10, 4.7 g of 1,6-dimethyl-5-valeryl-benzimidazole-2-methanol are mixed with 4.5 g of potassium permanganate to give 1,6-dimethyl-5-valeryl-benzimi-dazol 2-carboxylic acid of mp> 88 ° (decomp.) Oxidized.

13

637 643

Example 21 Example 29

In a manner analogous to that described in Example 19, a mixture of 62.9 g of diethyl pyrocarbonate, 100 ml starting from crude mononitro-4-chloro-2-methyl-butyro-triethylamine and 500 ml of acetonitrile can be mixed in with stirring.

phenone (about 75% of 4-chloro-2-methyl-5-nitro-butyro - within 5 minutes 19.1 g of 5-butyryl-6-methyl-benzimi-

phenone) via 4-ethylamino-2-methyl-5-nitro-butyrophenone s dazol-2-carboxylic acid. 118-121 °, the 1-ethyl-5-butyryl-6-methyl-benzimi- at room temperature, then 6 hours at the boil after-dazol-2-methanol of mp. 152-154 ° create. stir, evaporate to dryness under reduced pressure,

takes up in ethyl acetate, washes with sodium hydro-example 22 gene carbonate solution and twice with water, dries over

In an analogous manner to that described in Example 10, sodium sulfate can be evaporated, evaporated and recrystallized from acetic acid-5.2 g of l-ethyl-5-butyryl-6-methyl-benzimidazole-2-methanol with ethyl ester / methylene chloride. The 5-butyryl-6-4.5 g of potassium permanganate for 1-ethyl-5-butyryl-6-methyl-methyl-benzimidazole-2-carboxylic acid ethyl ester of mp.

-benzimidazole-2-carboxylic acid of mp.> 80 ° (dec.) 146-147 °.

oxidize.

15 Example 30

Example 23 22.2 g of 4-amino-2-methyl-5-nitro-butyrophenone are described in

230 ml of methanol can be dissolved in a manner analogous to that described in Example 13, 2 g of Raney nickel are added and, starting from 4-chloro-3-nitro-acetophenone, 4-butyl-15-25 ° at normal pressure until absorption of 4.9 liters of water

amino-3-nitro-acetophenone of mp 69-71 ° hydrogenated the 5-acetyl-1-n-serum. 20.8 g of ethoxy-butyl-benzimidazole-2-methanol of mp 121 ° -124 ° are prepared under nitrogen. Add 20 acetic acid, filter off the catalyst, evaporate under reduced pressure and heat at 130 ° for 3 hours. Example 24 After cooling, the mixture is dissolved in 200 ml of 2N hydrochloric acid and washed

In an analogous manner to that described in Example 10, it can be basified twice with ethyl acetate, made alkaline in the cold with 4.9 g of 5-acetyl-in-butyl-benzimidazole-2-methanol with 4.5 g of sodium carbonate and extracted twice with vinegar-potassium permanganate to 5-acetyl-ln-butyl-benzimidazole-2- 25 acid ethyl ester, dries over sodium sulfate, evaporates and oxidizes carboxylic acid with a melting point of> 75 ° (decomp.). chromatographed on 300 g silica gel. First elute a preliminary run with 1200 ml chloroform and then with 1200 ml Example 25 chloroform / ethanol (24: 1) the 2-ethoxymethyl-5-butyryl-6-

In an analogous manner to that described in Example 19, -methyl-benzimidazole, mp. 46-47 °.

starting from crude mononitro-4-chloro-2-methyl-30

-butyrophenone (about 50% 4-chloro-2-methyl-5-nitro- Example 31

-butyrophenone) via 4-butylamino-2-methyl-5-nitro-butyro- the in-butyl-5-butyryl-6-methyl to a solution of 18.9 g phenone of mp 80-82 ° cooled to 10 ° - 2-Ethoxymethyl-5-butyryl-6-methyl-benzimidazole in 380 ml -benzimidazole-2-methanol of mp. 78-81 °. Acetone, 9.5 ml pyridine and 5.7 ml water are stirred

35 ren 15 g of potassium permanganate added. Example 26 is left under ice cooling and 40 hours at room temperature.

In an analogous manner to that described in Example 10, the mixture can be stirred, filtered and evaporated to dryness under reduced pressure. 4.4 g of in-butyl-5-butyryl-6-methyl-benzimidazole-2-methanol are taken up in ethyl acetate and washed in succession To ln-butyl-5-butyryl-6-methyl-benzimidazole-2-carboxylic acid to pH = 6 buffered sodium bicarbonate solution and of mp.> 70 ° (dec.). 40 twice with water, dried over sodium sulfate and evaporated under reduced pressure. Then it is taken up in 30 ml of warm ethyl acetate, left to stand overnight and sucked in Example 27 crystalline 5-butyryl-6-methy-benzimidazole-2-carboxylic acid.

2.5 g of 5-butyryl-6-methyl-benzimidazole-2-carboxylic acid are ethyl ester of mp 137-139 °. The mother liquor can be dissolved in 100 ml of O, l-sodium hydroxide solution and 14.5 g of additional product with a melting point of 129-132 ° can be obtained. Ura-

Sodium carbonate added. To crystallize the resulting suspension from ethyl acetate / methylene chloride, 38 g of triethyl acid are increased in portions over 10 minutes to 146-147 °.

oxonium tetrafluoroborate added. The mixture is stirred for 30 minutes, extracted with ethyl acetate, washed two - Example 32

times with water, dried over sodium sulfate and evaporated to a mixture of 150 ml acetonitrile, 15 ml triethyl dryness. The evaporation residue is chromatographed on 100 g of silica gel amine and 18.5 g of diethyl pyrocarbonate with chloroform as the eluent. 6.0 g of 5-5-butylryl-6-methyl-benzimidazole-2-carboxylic acid ethyl-butyryl-l, 6-dimethyl-benzimidazole-2-carboxylic acid are added at room temperature within 15 minutes, ester of mp . 142-144 °. Allow to stand overnight, pull under reduced pressure

55 the acetonitrile, takes up in ethyl acetate, washed with water, dried over sodium sulfate and evaporated to dryness, for example 28. The initially oily, soon crystallizing

A mixture of 2.5 g of 5-butyryl-6-methyl-benzimidazole-5-butyryl-1,6-dimethyl-benzimidazole-2-carboxylic acid ethyl-2-carboxylic acid, 1.91 g of dimethylformamide diethyl acetal and 25 esters aspirated. It melts, from acetic acid-ml acetonitrile it is recrystallized with the exclusion of moisture and gel 60 ester / cyclohexane, at 106-108 °.

allowed to stand for 2 days at room temperature. The acetonitrile is removed under reduced pressure, and the residue is partitioned between ethyl acetate and Example 33

Sodium bicarbonate solution washes the neutral phase with in an analogous manner as described in Example 29

Water, evaporated and chromatographed on aluminum oxide for 6s starting from 10.1 g of 5-butyryl-1-methyl-benzimidazole-2-with chloroform / ethanol (9: 1) and 5-butyryl-6-carboxylic acid and 20 are obtained g diethyl pyrocarbonate the 5-ButyryI-l-

-methyl-benzimidazole-2-carboxylic acid ethyl ester of mp. -methyl-benzimidazole-2-carboxylic acid ethyl ester of mp.

142-144 °. 115-117 °. '

637 643

14

Example 34

In an analogous manner to that described in Example 32, 2-ethoxy-methyl-5-butyryl-1,6 is obtained starting from 23.6 g of 2-methyl-4-methylamino-5-nitro-butyrophenone and 10.4 g of ethoxyacetic acid -dimethyl-benzimidazole of mp. 46-47 °.

Example 35

23.4 g of 3,4-diamino-benzophenone and 12.7 g of glycolic acid are poured over with 16.5 ml of semi-concentrated hydrochloric acid and heated to 130-140 ° for 105 minutes. Pour, still hot, in 1500 ml of ice water, make alkaline with concentrated ammonia solution, stir for 60 minutes at room temperature and suction. The filter cake is boiled up with ethyl acetate, cooled and suction filtered again. 5 (6) -benzoyl-benzimidazole-2-methanol of mp 226-227 ° is obtained.

Starting from 20.8 g of 4-chloro-3-nitro-benzophenone, the starting material can be heated for 15 hours with 20 g of ammonia, dissolved in 290 g of methanol and 52 g of sulfolane, in a bomb tube to 125 ° and hydrogenating the 4 obtained in this way --Amino-3-nitrobenzophenone can be obtained at normal pressure in methanol and in the presence of Raney nickel. It melts at 80-83 °.

Example 37

5-Benzoyl-1-methyl-benzimidazole is obtained in an analogous manner to that described in Example 35, starting from 13.2 g of 3-amino-4-methylamino-benzophenone, 6.6 g of glycolic acid and 9.24 ml of semi-concentrated hydrochloric acid -l-methanol of mp. 168-172 °. This can be further purified on 30 times the amount of silica gel with ethyl acetate / acetone (7: 3) as the eluent and then melts at 176 °.

The starting material can be produced as follows:

11 g of 4-chloro-3-nitro-benzophenone, 20 g of methylamine, 153.4 g of methanol and 27.5 g of sulfolane are heated to 125 ° in a sealed vessel for 15 hours. The reaction solution is evaporated to dryness, the residue is boiled with 400 ml of 2N hydrochloric acid for 20 minutes, suction filtered, washed with water and dissolved in methylene chloride. After drying over sodium sulfate and evaporation, 4 - methylamino-3-nitro-benzophenone, mp. 198-201 °.

15.5 g of 4-methylamino-3-nitro-benzophenone in 350 ml of methanol are mixed with 3 g of Raney nickel and hydrogenated at 20-25 ° and normal pressure. After taking up 3.8 liters of hydrogen, the catalyst is filtered off and evaporated to dryness under reduced pressure. When rubbed in, 3-amino-4-methylamino-benzophenone crystallizes, which melts at 127-130 ° after suction filtering and drying.

Example 38

22 g of 2-methoxy-4-methylamino-5-nitro-butyrophenone are dissolved in 250 ml of methanol, mixed with 2 g of Raney nickel and hydrogenated at 35-40 ° under normal pressure. After taking up 5.9 liters of hydrogen, a solution of 12.9 g of glycolic acid in 20 ml of methanol is added under nitrogen, filtered off from the catalyst, evaporated to dryness and heated to 150 ° for 1 hour. The mixture is allowed to cool, dissolved in 100 ml of 2N hydrochloric acid, filtered, made alkaline with sodium hydroxide solution, extracted with 2000 ml of methylene chloride, concentrated under reduced pressure, mixed with ethyl acetate, the methylene chloride is completely stripped off, cooled and suctioned off and washed with Ethyl acetate / petroleum ether. The 5-butyryl-6-meth-oxy-l-methyl-benzimidazole-2-methanol melts at 179-184 °.

The starting material can be produced as follows:

Freshly prepared, still moist sodium methoxide from 0.23 g of sodium and 25 ml of methanol is suspended under nitrogen in 10 ml of hexamethylphosphoric triamide and with 2.45

g of 2-chloro-4-methylamino-5-nitro-butyrophenone were added. An exothermic reaction occurs. The mixture is stirred for 2 hours at room temperature, water is added and the mixture is extracted with ethyl acetate. It is washed with water, dried over 5 sodium sulfate, evaporated and recrystallized from ethyl acetate. The 2-methoxy-4-methylamino-5-nitro-butyro-phenone melts at 165-166 °.

Example 39

10 In an analogous manner to that described in Example 10, 5.2 g of 5-butyryl-6-methoxy-l-methyl-benzimidazole-2-methanol are mixed with 4.5 g of potassium permanganate to give 5-butyryl-6-methoxy-l-me- Oxidized thylbenzimidazole-2-carboxylic acid of mp. Above 85 ° (dec.).

15

Example 40

6.25 g of glycolic acid are added to a solution of 15.0 g of crude 5-amino-2-methyl-4-methylamino-cyclopropylcarbonylbenzene in 200 ml of absolute methanol. The mixture is then stirred under a nitrogen atmosphere at 35 ° for 15 minutes and evaporated to dryness under reduced pressure. The crystalline residue is heated to 130 ° and stirred for three hours at this temperature. The melt is cooled and dissolved in 300 ml of 2N hydrochloric acid. The 25 acidic solution is made alkaline with 2N sodium carbonate solution. The separated oil is extracted with methylene chloride, the organic extract is washed with water, dried over magnesium sulfate and concentrated to dryness under reduced pressure. The residue is chromatographed on 30,400 g of silica gel with methylene chloride / methanol (9: 1) as the eluent. Fractions of 700 ml are collected. The 5-cyclopropylcarbonyl-l, 6-dimethyl-benzimidazole-2-me-ethanol is contained in fractions 3-8, which are combined and evaporated under reduced pressure. The compound melts, crystallized from ethyl acetate, at 143-144 °.

The starting material can be produced as follows:

A suspension of 428 g of 3-chlorotoluene and 174.6 g of pul-40 verified aluminum chloride is mixed with 124 g of cyclopropanecarboxylic acid chloride within one hour. The reaction mixture is then heated to 50 ° for one hour and poured onto 1000 g of ice. The excreted oil is extracted with 1000 ml ether. The separated organic phase is washed twice with 200 ml of 2N hydrochloric acid, 200 ml of 2N sodium carbonate solution and water, dried over magnesium sulfate and concentrated to dryness. The residue thus obtained is distilled. A mixture of the 4-chloro-2-methyl-cyclopropylcarbonyl-benzene and the Isome-50 ren 2-chloro-4-methylcyclopropylcarbonyl-benzoIs is obtained in a ratio of 2: 1. 100-102 ° / 0.05 mm Hg.

123 g of a mixture of isomers of 4-chloro-2-methylcyclo-propylcarbonyl-benzene and 2-chloro-4-methyl-cyclopropylcarbonyl-benzene are added dropwise with good stirring to 538 55 ml of concentrated sulfuric acid, which are at -20 ° to -25 ° has cooled, added. A mixture of 31.3 ml of 100% nitric acid (d: 1.52) and 101.2 ml of concentrated sulfuric acid is added to the solution at −20 ° to −25 ° within 30 minutes and the mixture is then stirred for a further 60 minutes with the temperature rising to -10 °. The mixture is poured onto 6000 ml of water and the oil which has separated out is extracted with 2000 ml of ether. The organic phase is washed twice with water, then twice with 300 ml of 2N potassium hydrogen carbonate solution and again with water, dried over magnesium sulfate and evaporated. The residue, an oil, consists of a mixture which, in addition to about 2/3 4-chloro-2-methyl-5-nitro-cyclopropylcarbonylbenzene, is an isomer, probably the 2-chloro-4-methyl-5-

15

637 643

contains -cyclopropylcarbonyl-benzene and is reacted further without further purification.

127 g of this 4-chloro-2-methyl-5-nitro-cyclopropylcarbonyl-benzene in addition to 2-chloro-4-methyl-5-nitro-cyclopropylcarbonyl-benzene containing isomer mixture is mixed with 600 ml of a 33% solution of methylamine added to ethanol. The oily starting material dissolves and a yellow color appears. The mixture is left to stand at room temperature for 30 minutes and then concentrated to dryness under reduced pressure. The residue is mixed with 2000 ml of methylene chloride, ice and sodium carbonate, shaken and the organic phase separated. This is washed with water, dried over magnesium sulfate and evaporated to dryness under reduced pressure. The residue is crystallized from ethyl acetate. The 2-methyl-4-methylamino-5-nitro - cyclopropylcarbonyl-benzene melts at 144-148 °.

A solution of 5-nitro-2-methyl-4-methylamino-cyclo-propylcarbonyl-benzene in 280 ml of methanol is hydrogenated for 8 hours at 25 ° and normal pressure after the addition of 2.8 g of Raney nickel. After the hydrogenation has ended, the catalyst is filtered off in a nitrogen atmosphere and the methanolic solution of the unstable 5-amino-2-methyl-4-methylamino-cyclo-propylcarbonyl-benzene is immediately reacted further.

Example 41

A solution of 1.6 g of 5-cyclopropyl-carbonyl-6-methyl-benzimidazole-2-methanol in 93 ml of acetone is diluted with 72 ml of water with stirring. This solution is mixed with 1.6 g of potassium permanganate and stirred at room temperature for 15 hours. The suspension is then concentrated under reduced pressure to about 70 ml and filtered through a layer of diatomaceous earth. Then it is washed with 40 ml of water and the aqueous filtrate is acidified with 2N hydrochloric acid. The precipitate formed is filtered off, washed with 10 ml of water, suspended in 10 ml of cold methanol and filtered off again. The 5-cyclopropylcarbonyl-6-methyl-benzimi-dazol-2-carboxylic acid melts at 89-92 ° (dec.).

Example 42

A solution of 5.0 g of 5-butyryl-l, 6-dimethyl-benzimi-dazol-2-methanol in 100 ml of methylene chloride is mixed with 2.36 g of acetyl chloride, stirred for one hour at room temperature and then mixed with 5 ml of triethylamine. The mixture is stirred for 30 minutes, shaken with sodium bicarbonate solution and twice with water, dried over sodium sulfate and evaporated. 2-Acetoxymethyl-5-butyryl-1,6-dimethyl-benzimidazole of mp 95.5-96 ° is obtained.

Example 43

27.8 g of 2-methyl-4-methylamino-5-nitro-oenanthophenone, dissolved in 300 ml of methanol, are mixed with 9 g of Raney nickel and at 20 ° to 25 ° under normal pressure until 6.8 liters of hydrogen are taken up hydrated. A solution of 15 g of glycolic acid in 50 ml of methanol is added to the hydrogenation solution under nitrogen, the catalyst is filtered off and the mixture is evaporated under reduced pressure. The evaporation residue is heated to 130 ° under nitrogen for 90 minutes, dissolved in 2N hydrochloric acid after cooling, filtered, made alkaline with concentrated sodium hydroxide solution and extracted with methylene chloride. The organic phases are collected, washed twice with water, dried over sodium sulfate and evaporated. The 1,6-dimethyl-5-oenanthyl-benzimidazole-2-methanol of mp. 93-93.5 ° is obtained.

The starting material can be produced as follows:

60.6 g of 4-chloro-2-methyl-benzonitrile, dissolved in 60 ml of diethyl ether, become a boiling solution of n-hexyl-magnesium bromide, made from 12.1 g of magnesium shavings and 82.5 g of 1-bromohexane in 125 ml Diethyl ether, added dropwise. The reaction mixture is heated to boiling for 5 hours. After cooling, 150 ml of 4N hydrochloric acid are added dropwise. The mixture is stirred for 60 minutes, left to stand overnight, the ether phase is separated off, the water phase is washed with ether, the combined ether phases are washed with water, dried over sodium sulfate, evaporated and distilled. The 4-chloro-2-methyl-oenanthophenone changes at Kpi0 = 165-170 °.

67.7 g of 4-chloro-2-methyl-oenanthophenone are dissolved in 285 ml of sulfuric acid cooled to -15 to -10 ° and a mixture of 16.3 ml of fuming nitric acid and 53 ml of sulfuric acid is added dropwise within 15 minutes. The mixture is stirred at -15 ° for 30 minutes, poured into 1500 ml of ice water and extracted with methylene chloride. The organic phase is washed successively with water, sodium bicarbonate solution and twice with water, dried over sodium sulfate and evaporated. The 4-chloro-2-methyl-5-nitro-oenanthophenone can be reacted further without further purification.

78.8 g of 4-chloro-2-methyl-5-nitro-oenanthophenone are dissolved in 600 ml of ethanol, mixed with 200 ml of a 33% aqueous methylamine solution, heated on a water bath for 60 minutes and left overnight at room temperature. It is evaporated to dryness, heated to 80 to 90 ° for 60 minutes with 300 ml of 2N hydrochloric acid, cooled to 10 to 15 ° by adding ice, suction filtered, taken up in methylene chloride, dried over sodium sulfate, evaporated to dryness again, and triturated with 200 ml of petroleum ether (60-80 °) and filter the 2-methyl-4-methylamino-5-nitro-oenanthophenone from mp. 77-79 °.

Example 44

The following can also be prepared in an analogous manner to that described in Examples 1 to 43:

5-propionyl-l, 6-dimethyl-benzimidazole-2-methanol, mp 139-140 °;

5-isobutyryl-l, 6-dimethyl-benzimidazole-2-methanol, mp. 158-160 °;

5- (2-methylbutyryl) -1, 6-dimethyl-benzimidazole-2-methanol, mp 158 °;

5-isovaleryl-l, 6-dimethyl-benzimidazole-2-methanol, mp 142-142.5 °;

5-butyryl-l, 6-dimethyl-benzimidazole-2-carboxylic acid isopropyl ester, mp 90-91 °; 5-butyryl-l, 6-dimethyl-benzimidazole-2-carboxylic acid (l-dimethylamino) -2-propyl ester; 5-propionyl-l, 6-dimethyl-benzimidazole-2-carboxylic acid; 5-isobutyryl-l, 6-dimethyl-benzimidazole-2-carboxylic acid; 5-butytyl-6-hydroxy-l-methyl-benzimidazole-2-carboxylic acid; 5-butyryl-6-hydroxy-l-methyl-benzimidazole-2-methanol; 1,6-dimethyl-5- (4-methylthiobutyryl) benzimidazole-2-methanol; 5-butyryl-l, 6-dimethyl-2- (2-dimethylaminoethoxymethyl) benzimidazole, mp. 108 °;

5-acetyl-6-methyl-benzimidazole-2-carboxylic acid;

6-methyl-5-propionyl-benzimidazole-2-carboxylic acid; 5-butyryl-6-methoxy-benzimidazole-2-carboxylic acid; 5-butyryl-6-chloro-benzimidazole-2-carboxylic acid; 5-cyclopropylcarbonyl-6-methyl-benzimidazole-2-carboxylic acid; 5-cyclohexylcarbonyl-6-methyl-benzimidazole-2-carboxylic acid;

5- (4-methoxy-butyryl) -6-methyl-benzimidazole-2-carboxylic acid;

6-methyl-5- (4-methylthio-butyryl) benzimidazole-2-carboxylic acid; 6-methyl-5- (4-methylsulfinyl-butyryl) benzimidazole-2-carbon

acid;

6-methyl-5- (4-phenylthio-butyryl) benzimidazole-2-carboxylic acid; 6-methyl-5- (4-phenylsulfinyl-butyryl) benzimidazole-2-carboxylic acid;

and

5-Butyryl-6-methyl-benzimidazole-2-carboxylic acid methyl ester. A 2% aqueous solution of the

5

10th

15

20th

25th

30th

35

40

45

50

55

60

65

637 643

16

Sodium salt of 5-butyryl-l, 6-dimethyl-benzimidazole-2-car-bonic acid can be prepared as follows:

Composition (for 100 ml)

Sodium salt of 5-butyryl-l, 6-dimethyl-benzimidazole-2-carboxylic acid 2,000 g

Disodium salt of ethylenediamine-tetra-acetic acid (stabilizer) 0.010 g

Benzalkonium chloride (preservative) 0.010 g

Water, distilled ad 100 ml

The sodium salt of 5-butyryl-l, 6-dimethyl-benzimidazole - 2-carboxylic acid is dissolved in freshly distilled water, and the solution with the disodium salt of ethylenediamine-tetra-acetic acid and the benzalkonium chloride (mixture of alkyl - dimethylbenzylammonium chlorides , wherein alkyl contains 8 to 18 carbon atoms). After the components have completely dissolved, the solution obtained is brought to a volume of 100 ml with water, filled and sealed gas-tight.

In an analogous manner, 2% aqueous inhalation solutions of the sodium salt of 5 (6) -valeryl-benzimidazole-2-carboxylic acid,

5-acetyl-6-methyl-benzimidazole-2-carboxylic acid,

6-methyl-5-propionyl-benzimidazole-2-carboxylic acid, 6-methyl-5-valeryl-benzimidazole-2-carboxylic acid, 5 (6) -butyryl-benzimidazole-2-carboxylic acid, 5-butyryl-6-methoxy-benzimidazole -2-carboxylic acid, 5-butyryl-6-chloro-benzimidazole-2-carboxylic acid, 5-cyclopropylcarbonyl-6-methyl-2-benzimidazole-2-carboxylic acid, 5-cyclohexylcarbonyl-6-methyl-2-benzimidazole-2-carboxylic acid ,

5- (4-methoxybutyryl) -6-methyl-2-benzimidazole-2-carboxylic acid,

6-methyl-5- (4-methylthiobutyryl) benzimidazole-2-carboxylic acid, 6-methyl-5- (4-methylsulfinylbutyryl) benzimidazole-2-carbon-

acid,

6-methyl-5- (4-phenylthiobutyryl) benzimidazole-2-carboxylic acid, 6-methyl-5- (4-phenylsulfinylbutyryl) benzimidazole-2-carboxylic acid,

5-acetyl-l-methyl-benzimidazole-2-carboxylic acid, 5-butyryl-l-methyl-benzimidazole-2-carboxylic acid, 5-butyryl-6-chloro-l-methyl-benzimidazole-2-carboxylic acid, l, 6- Dimethyl-5-valeryI-benzimidazole-2-carboxylic acid, l-ethyl-5-butyryl-6-methyl-benzimidazole-2-carboxylic acid, 5-acetyl-l-butyl-benzimidazole-2-carboxylic acid, l-butyl-5-butyryl -benzimidazole-2-carboxylic acid, 5 (6) -benzoyl-benzimidazole-2-carboxylic acid, 5-cyclopropylcarbonyl-l, 6-dimethyl-benzimidazole-2-carboxylic acid and

Prepare 5-butyryl-6-hydroxy-l-methyl-benzimidazole-2-carboxylic acid.

A 2% aqueous solution of 5-butyryl-1, 6-dimethyl-benzimidazole-2-methanol suitable for inhalation can be prepared as follows:

Composition (for 100 ml)

5-butyryl-l, 6-dimethyl-benzimidazole-2-methanol 2.000 g disodium salt of ethylenediamine-tetra-

acetic acid (stabilizer) 0.010 g

Benzalkonium chloride (preservative) 0.010 g

Water, distilled ad 100 ml

The 5-butyryl-1, 6-dimethyl-benzimidazole-2-methanol is added with the addition of a solubilizer, e.g. Polyethylene glycol dissolved in freshly distilled water, and the solution with the disodium salt of ethylenediamine-tetraacetic acid and the benzalkonium chloride (mixture of alkyl-dimethyl-benzyl-ammonium chlorides, in which alkyl contains 8 to 18 carbon atoms). After the components have completely dissolved, the solution obtained is brought to a volume of 100 ml with water, filled and sealed gas-tight.

In an analogous manner, 2% aqueous inhalation solutions from

5-butyryl-6-methyl-benzimidazole-2-methanol, 5 (6) -valeryl-benzimidazole-2-methanol,

6-methyl-5-valeryl-benzimidazole-2-methanol, 5 (6) -butyryl-benzimidazole-2-methanol, 5-acetyl-l-methyl-benzimidazole-2-methanol, 5-butyryl-1-methyl-benzimidazole -2-methanol 5-butyryl-6-chloro-l-methyl-benzimidazole-2-methanol l, 6-dimethyl-5-valeryl-benzimidazole-2-methanol, l-ethyl-5-butyryl-6-methyl-benzimidazole -2-methanol 5-acetyl-1-butyl-benzimidazole-2-methanol,

1-butyl-5-butyryl-6-methyl-benzimidazole-2-methanol, 5-benzoyl-benzimidazole-2-methanol, 5-butyryl-6-methoxy-l-methyl-benzimidazole-2-methanol, l, 6- Dimethyl-5-oenanthyl-benzimidazole-2-methanol, 5-cyclopropylcarbonyl-l, 6-dimethyl-benzimidazole-2-methanol,

2-ethoxymethyl-5-butyryl-6-methyl-benzimidazole, 2-ethoxymethyl-5-butyryl-1,6-dimethyl-benzimidazole, 2-acetoxymethyl-5-butyryl-l, 6-dimethyl-benzimidazole, 5-butyryl- 6-hydroxy-l-methyl-benzimidazole-2-methanol, l, 6-dimethy-5- (4-methylthiobutyryl) benzimidazole-2-methanol, 5-butyryl-l, 6-dimethyl-2- (2-dimethylaminoethoxy -methyl)-

-benzimidazole,

5-butyryl-6-methyl-benzimidazole-2-carboxylic acid ethyl ester, 5-butyryl-1, 6-dimethyl-benzimidazole-2-carboxylic acid ethyl ester, 5-butyryl-1-methyl-benzimidazole-2-carboxylic acid ethyl ester and

Prepare 5-butyryl-6-methyl-benzimidazole-2-carboxylic acid methyl ester.

0.025 g of capsules containing 5-butyryl-1, 6-dimethyl-benzimidazole-2-carboxylic acid suitable for insufflation can be prepared as follows:

Composition (for 1000 capsules)

5-butyryl-l, 6-dimethyl-benzimidazole-2-carboxylic acid 25.00 g lactose, ground 25.00 g

The 5-butyryl-l, 6-dimethyl-benzimidazole-2-carboxylic acid and the lactose (very finely ground) are mixed well with one another. The powder obtained is then sieved and the portions of 0.05 g each are filled into gelatin capsules.

In an analogous manner, insufflation capsules each containing 0.025 g of 5 (6) -valeryl-benzimidazole-2-carboxylic acid,

5-acetyl-6-methyl-benzimidazole-2-carboxylic acid,

6-methyl-5-propionyl-benzimidazole-2-carboxylic acid, 6-methyl-5-valeryl-benzimidazole-2-carboxylic acid, 5 (6) -butyryl-benzimidazole-2-carboxylic acid, 5-butyryl-6-methoxy-benzimidazole -2-carboxylic acid, 5-butyryl-6-chloro-benzimidazole-2-carboxylic acid, 5-cyclopropylcarbonyl-6-methyl-benzimidazole-2-carboxylic acid, 5-cyclohexylcarbonyI-6-methyl-benzimidazole-2-carboxylic acid,

5- (4-methoxybutyryl) -6-methyl-benzimidazole-2-carboxylic acid,

6-methyl-5- (4-methylthiobutyryl) benzimidazole-2-carboxylic acid, 6-methyl-5- (4-methylsulfinylbutyryl) benzimidazole-2-carbon-

acid,

6-methyl-5- (4-phenylthiobutyryl) benzimidazole-2-carboxylic acid, 6-methyl-5- (4-phenylsulfinylbutyryl) benzimidazole-2-carboxylic acid,

5-butyryl-6-methyl-benzimidazole-2-carboxylic acid methyl ester, 5-butyryl-6-methyl-benzimidazole-2-methanol,

5-butyl 1-1,6-dimethyl-benzimidazole-2-methanol, 5 (6) -valeryl-benzimidazole-2-methanol,

6-methyl-5-valeryl-benzimidazole-2-methanol,

5

10th

15

20th

25th

30th

35

40

45

50

55

60

65

17th

637 643

5 (6) -butyryl-benzimidazole-2-methanol,

5-acetyl-l-methyl-benzimidazole-2-methanol,

5-butyryl-l-methyl-benzimidazole-2-methanol,

5-butyryl-6-chloro-l-methyl-benzimidazole-2-methanol,

l, 6-dimethyl-5-valeryl-benzimidazole-2-methanol,

l-ethyl-5-butyryl-6-methyl-benzimidazole-2-methanol,

5-acetyl-1-butyl-benzimidazole-2-methanol,

1-butyl-5-butyryl-6-methyl-benzimidazole-2-methanol, 5-benzoyl-benzimidazole-2-methanol, 5-benzoyl-l-methyl-benzimidazole-2-methanol, 5-butyryl-6-methoxy- l-methyl-benzimidazole-2-methanol, 5-cyclopropylcarbonyl-l, 6-dimethyl-benzimidazole-2-methanol,

2-ethoxymethyl-5-butyryl-6-methyl-benzimidazole, 2-ethoxymethyl-5-butyryl-l, 6-dimethyl-benzimidazole, 2-acetoxymethyl-5-butyryl-l, 6-dimethyl-benzimidazole, 5-butyryl- 6-hydroxy-1-methyl-benzimidazole-2-methanol, 1,6-dimethyl-5- (4-methylthiobutyryl) -benzimidazole-2-methanol, 5-butyryl-1,6, 6-dimethyl-2- (2-dimethylaminoethoxymethyl ) -

-benzimidazole,

5-acetyl-l-methyl-benzimidazole-2-carboxylic acid,

5-butyryl-l-methyl-benzimidazole-2-carboxylic acid,

5-butyryl-6-chloro-l-methyl-benzimidazole-2-carboxylic acid,

l, 6-dimethyl-5-valeryl-benzimidazole-2-carboxylic acid,

l-ethyl-5-butyryl-6-methyl-benzimidazole-2-carboxylic acid,

5-acetyl-1-butyl-benzimidazole-2-carboxylic acid,

l, 6-dimethyl-5-oenanthyl-benzimidazole-2-methanol,

l-butyl-5-butyryl-benzimidazole-2-carboxylic acid,

5 (6) -benzoyl-benzimidazole-2-carboxylic acid,

5-cyclopropylcarbonyl-l, 6-dimethyl-benzimidazole-carboxylic acid,

5-butyryl-6-hydroxy-l-methyl-benzimidazole-2-carboxylic acid,

5-butyryl-6-methyl-benzimidazole-2-carboxylic acid ethyl ester,

5-butyryl-1,6-dimethyl-benzimidazole-2-carboxylic acid ethyl ester and

Prepare 5-butyryl-l-methyl-benzimidazole-2-carboxylic acid ethyl ester.

Tablets containing 100 mg of butyryl-l, 6-dimethyl-benzimi-dazol-2-carboxylic acid or its sodium salt (active ingredient) can be prepared, for example, in the following composition:

Composition Per tablet of active ingredient, e.g. 5-butyryl-l, 6-dimethyl

-benzimidazole-2-carboxylic acid 100 mg

Milk sugar 50 mg

Wheat starch 73 mg

Colloidal silica 13 mg

Talc 12 mg

Magnesium stearate 2 mg

250 mg

Manufacturing

The active ingredient is mixed with the milk sugar, part of the wheat starch and with colloidal silica and the mixture is passed through a sieve. Another part of the wheat starch is gelatinized with 5 times the amount of water on the water bath and the powder mixture is kneaded with this paste until a weak plastic mass has formed. The mass is passed through a sieve of approx. 3 mm mesh size, dried and the dry granules are again passed through a sieve. The remaining wheat starch, talc and magnesium stearate are then mixed in. The mixture obtained is pressed into tablets of 250 mg with a notch (s).

Tablets containing 100 mg each of the compounds listed below can also be prepared in an analogous manner, these also being in the form of pharmaceutically acceptable salts, such as acid addition salts, e.g. the hydrochloride, or, in the case of carboxylic acids, salts with base, e.g. Sodium salts can be used: 5-butyryl-6-methyl-benzimidazole-2-carboxylic acid, 5 (6) -valeryl-benzimidazole-2-carboxylic acid,

5-acetyl-6-methyl-benzimidazole-2-carboxylic acid,

6-methyl-5-propionyl-benzimidazole-2-carboxylic acid, 6-methyl-5-valeryl-benzimidazole-2-carboxylic acid, 5 (6) -butyryl-benzimidazole-2-carboxylic acid, 5-butyryl-6-methoxy-benzimidazole -2-carboxylic acid, 5-butyryl-6-chloro-benzimidazole-2-carboxylic acid, 5-cyclopropylcarbonyl-6-methyl-benzimidazole-2-carboxylic acid, 5-cyclohexylcarbonyl-6-methyl-benzimidazole-2-carboxylic acid,

5- (4-methoxybutyryl) -6-methyl-benzimidazole-2-carboxylic acid,

6-methyl-5- (4-methylthiobutyryl) benzimidazole-2-carboxylic acid, 6-methyl-5- (4-methylisulfinyIbutyryl) benzimidazole-2-carbon-

acid,

6-methyl-5- (4-phenylthiobutyryl) benzimidazole-2-carboxylic acid, 6-methyl-5- (4-phenylsulfinylbutyryl) benzimidazole-2-carboxylic acid,

5-butyryl-6-methyl-benzimidazole-2-carboxylic acid methyl ester, 5-butyryl-6-methyl-benzimidazole-2-methanol,

5-butyryl-l, 6-dimethyl-benzimidazole-2-methanol, 5 (6) -V aleryl-benzimidazole-2-methanol,

6-methyl-5-valeryl-benzimidazole-2-methanol, 5 (6) -butyryl-benzimidazole-2-methanol, 5-acetyl-l-methyl-benzimidazole-2-methanol, 5-butyryl-1-methyl-benzimidazole -2-methanol, 5-butyryl-6-chloro-l-methyl-benzimidazole-2-methanol, l, 6-dimethyl-5-valeryl-benzimidazole-2-methanol, l-ethyl-5-butyryl-6-methyl benzimidazole-2-methanol, 5-acetyl-1-buatyl-benzimidazole-2-methanol,

1-butyl-5-butyryl-6-methyl-benzimidazole-2-methanol, l, 6-dimethyl-5-oenanthyl-benzimidazole-2-methanol, 5-benzoyl-benzimidazole-2-methanol, 5-benzoyl-l- methy-benzimidazole-2-methanol, 5-butyryl-6-methoxy-l-methyl-benzimidazole-2-methanol, 5-cyclopropylcarbonyl-l, 6-dimethyl-benzimidazole-2-methanol,

2-ethoxymethyl-5-butyryl-6-methyl-benzimidazole, 2-ethoxymethyl-5-butyryl-l, 6-dimethyl-benzimidazole, 2-acetoxymethyl-5-butyryl-l, 6-dimethyl-benzimidazole, 5-butyryl- 6-hydroxy-l-methyl-benzimidazole-2-methanol, l, 6-dimethyl-5 (4-methylthiobutyryl) -benzimidazole-2-methanol, 5-butyryl-l, 6-dimethyl-2- (2-dimethylaminoethoxymethyl) -

-benzimidazole,

5-acetyl-l-methyl-benzimidazole-2-carboxylic acid, 5-butyryl-l-methyl-benzimidazole-2-carboxylic acid, 5-butyryl-6-chloro-l-methyl-benzimidazole-2-carboxylic acid, l, 6- Dimethyl-5-valeryl-benzimidazole-2-carboxylic acid, l-ethyl-5-butyryl-6-methyl-benzimidazole-2-carboxylic acid, 5-acetyl-l-butyl-benzimidazole-2-carboxylic acid, l-butyl-5- butyryl-benzimidazole-2-carboxylic acid, 5 (6) -benzoyl-benzimidazole-2-carboxylic acid, 5-cyclopropylcarbonyl-l, 6-dimethyl-benzimidazole-2-carboxylic acid,

5-butyryl-6-hydroxy-l-methyl-benzimidazole-2-carboxylic acid, 5-butyryl-6-methyl-benzimidazole-2-carboxylic acid ethyl ester, 5-butyryl-l, 6-dimethyl-benzimidazole-2-carboxylic acid ethyl ester or

5-Butyryl-1-methyl-benzimidazole-2-carboxylic acid ethyl ester.

5

10th

15

20th

25th

30th

35

40

45

50

55

60

V

Claims (20)

637 643 1 * / wherein R 'carboxy, as etherified hydroxyl group, lower alkoxy having up to 4 carbon atoms, esterified carboxy, as amino group, amino or hydroxyamino, amidated carboxy, hydroxymethyl, as etherified hydroxyl group, lower alkoxy, having up to 4 carbon atoms, or di-lower alkylamino lower alkoxy, with up to 7 carbon atoms, etherified hydroxyl 2. Compounds according to claim 1 of formula I, wherein R for carboxy or hydroxymethyl, as etherified hydroxyl group, lower alkoxy, hydroxy-lower alkoxy, lower alkoxynie-deralkoxy or di-lower alkylamino-lower alkoxy having esterified carboxy or etherified hydroxymethyl, as amino group, amino, hydroxyamino, lower alkylamino, dinie deralkylamino or lower alkylamino having amidated carboxy or lower alkanoyloxy as the esterified hydroxy group or esterified hydroxymethyl containing benzoyloxy optionally substituted by lower alkyl, lower alkoxy and / or hylogen, Ri optionally substituted by lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, phenylsulfonyl or phenylsulfonylylphenyl, phenylsulfonylylphenyl, phenylsulfonylylphenyl, phenylsulfonylylphenyl, phenylsylylphenyl or phenylsulfonylylphenyl, phenylsylylphenyl, phenylsylylphenyl, , Cycloalkyl, optionally substituted in the phenyl radical by lower alkyl, lower alkoxy or halogen, phenyl or phenyl-lower alkyl, furyl, thienyl or pyridyl, or furyl-lower alkyl, thienyl-lower alkyl or pyridyl-lower ralkyl means R2 represents hydrogen or lower alkyl, and Ph represents the remainder of the formula Ri-C (= O) - containing and optionally additionally substituted by lower alkyl, lower alkoxy, hydroxy and / or halogen 1,2-phenylene. * 2 wherein R represents an optionally esterified or amidated carboxy group or an optionally etherified or esterified hydroxymethyl group, Ri represents an aliphatic, cyclo-aliphatic, aromatic, araliphatic, heterocyclic, heterocyclic-aliphatic radical, R2 represents hydrogen or an aliphatic radical, and Ph represents a 1,2-phenylene group containing the radical Ri-C (C = O) - and optionally also further substituents, with the proviso that Ri has at least 2 carbon atoms if Ph is otherwise unsubstituted, R2 is ethyl and R is acetoxy-methyl represents, or a salt of such a compound with salt-forming properties. 2nd PATENT CLAIMS 1. Benzimidazole-2 derivatives of the formula Ri - C - Ph ^ 'C - R W> N I 3rd 637 643 or as an esterified hydroxyl group, lower alkanoyloxy having up to 7 carbon atoms is esterified hydroxymethyl, R 1 'lower alkyl having up to 7 carbon atoms, lower alkoxy lower alkyl, lower alkylthione lower alkyl, lower alkylsulfinyl lower alkyl, phenylthione lower alkyl or phenylsulfinyl lower alkyl, in which the lower alkyl radicals contain up to 4 carbon atoms and contain cyclo 3. Compounds according to claim 1 of formula I, wherein R is hydroxymethyl or lower alkoxymethyl, Rj optionally substituted by lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, phenylthio, phenylsulfinyl or phenylsulfonyl, lower alkyl, lower alkenyl, cycloalkyl, optionally in the phenyl radical by lower alky, lower alkoxy or halogen substituted phenyl or phenyl-lower alkyl, furyl, thienyl or pyridyl, or furyl-lower alkyl, thienyl-lower alkyl or pyridyl-lower alkyl, R2 represents hydrogen or lower alkyl, and Ph for the rest of the formula containing Ri-C (= 0) - and optionally additionally by lower alkyl, lower alkoxy and / or halogen-substituted 1,2-phenylene. 4. Compounds according to claim 1 of formula I, in which R represents carboxy, as etherified hydroxy group lower alkoxy or hydroxy lower alkoxy having up to 4 carbon atoms and esterified carboxy, as amino group amino or hydroxyamino, lower alkylamino or di-lower alkylamino, in which lower alkyl contains up to 4 carbon atoms, having amidated carboxy or hydroxymethyl, as etherified hydroxy group lower alkoxy having up to 4 carbon atoms or di-lower alkylamino lower alkoxy each having up to 4 carbon atoms in the alkyl or alkoxy part, etherified hydroxymethyl or as esterified hydroxy group lower alkanoyloxy having up to 7 carbon atoms or optionally by lower alkyl having up to 4 carbon atoms, lower alkoxy having up to 4 carbon atoms and / or halogen up to atom number 35 is benzoyloxy-substituted esterified hydroxymethyl, Ri is lower alkyl having up to 7 carbon atoms, lower alkoxy, lower alkylthio, lower ralkylsulfinyl- or lower alkylsulfonyl-lower alkyl, in which the individual lower alkyl radicals contain up to and with 4 carbon atoms, phenylthio-, Phenylsulfinyl- or phenylsulfonyl-lower alkyl, in which the lower alkyl radical contains up to and with 4 carbon atoms, lower alkenyl with up to and with 5 carbon atoms, cycloalkyl with up to and with 7 carbon atoms, optionally by lower alkyl with up to and with 4 carbon atoms, lower alkoxy with up to and with 4 carbon atoms and / or halogen with atom number up to and including 35 substituted phenyl or phenyl-lower alkyl with up to and with 4 carbon atoms in the lower alkyl radical, furyl, thienyl or pyridyl, or furyl, thienyl or pyridyl-lower alkyl with up to and with 4 carbon atoms in the lower alkyl radical, R2 Represents hydrogen or lower alkyl with up to and with 4 carbon atoms, and Ph that contains the rest of the formula Ri-C (= 0) - and optionally additionally with lower alkyl with up to and with 4 carbon atoms, lower alkoxy with up to and with 4 carbon atoms, Hydroxy and / or halogen with atomic numbers up to and including 35 substituted 1,2-phenylene. 5 5. Compounds according to claim 1 of formula I, in which R is hydroxymethyl or etherified hydroxymethyl having lower alkoxy having up to 4 carbon atoms, Rj lower alkyl having up to and with 7 carbon atoms, lower alkoxy, lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl lower alkylsulfonyl lower alkyl, in which the individual lower alkyl radicals contain up to and with 4 carbon atoms, phenylthio, phenylsulfinyl or phenylsulfonyl lower alkyl, in which the lower alkyl radical contains up to and with 4 carbon atoms, lower alkenyl with up to and with 5 carbon atoms, cycloalkyl with up to and with 7 carbon atoms, if appropriate by lower alkyl with up to and with 4 carbon atoms, lower alkoxy with up to and with 4 carbon atoms and / or halogen with atom numbers up to and with 35 substituted phenyl or phenyl-lower alkyl with up to and with 4 carbon atoms in the lower alkyl radical, furyl, thienyl or pyridyl, or furyl , Thienyl or pyridyl-ni e-deralkyl with up to and with 4 carbon atoms in the lower alkyl radical, R2 represents hydrogen or lower alkyl with up to and with 4 carbon atoms, and Ph which contains the radical of the formula RrC (= O) - and optionally additionally with lower alkyl with up to and with 4 carbon atoms, lower alkoxy with up to and including 4 carbon atoms and / or halogen with atom numbers up to and including 35 substituted 1,2-phenylene. 6 represents ring carbon atoms, phenyl, furyl or pyridyl, R2 'represents hydrogen or lower alkyl having up to and with 4 carbon atoms, and R3 is hydrogen, lower alkyl having up to and with 4 carbon atoms, lower alkoxy having up to and with 4 carbon atoms, hydroxy or halogen with atom number up to and with 35 means with the proviso that Ri 'has at least 2 carbon atoms when R3 is hydrogen, R2' is ethyl and R 'is acetoxymethyl. 6. Compounds according to claim 1 of the formula ° / v \ R'-C | - H C-R1 (Ia), 7 carbon atoms, cycloalkyl with up to and with 6 ring carbon atoms or phenyl, R2 'represents hydrogen or lower alkyl with up to and with 4 carbon atoms, and R3 is hydrogen, lower alkyl with up to and with 4 carbon atoms, lower alkoxy with up to and with 4 carbon atoms or halogen with Atom number up to 35 means. 7. Compounds according to claim 6 of the formula Ia, in which R 'is hydroxymethyl or etherified hydroxymethyl having lower alkoxy having up to 4 carbon atoms, Ri' lower alkyl having up to 7 carbon atoms, lower alkoxy-lower alkyl, lower alkylthione-lower alkyl, lower alkylsulfinyl-lower alkyl, phenylthione-lower alkyl or phenylsulfinyl-lower alkyl, Contain lower alkyl radicals up to and with 4 carbon atoms, cycloaklyl with up to and with 6 ring carbon atoms, phenyl, furyl or pyridyl, R2 'represents hydrogen or lower alkyl with up to and with 4 carbon atoms, and R3 is hydrogen, lower alkyl with up to and with 4 carbon atoms, lower alkoxy with up to and with 4 carbon atoms or halogen with atomic number up to and with 35 means. 8. Compounds according to claim 6 of the formula Ia, in which R 'is carboxy, hydroxymethyl or, as etherified hydroxyl group, lower alkoxy having up to 4 carbon atoms and having esterified carboxy or etherified hydroxymethyl, Ri' is lower alkyl having up to 7 carbon atoms, cycloalkyl having up to 6 Ring carbon atoms or phenyl means R2 'is hydrogen or lower alkyl with up to and with 4 carbon atoms, and R3 is hydrogen, lower alkyl with up to and with 4 carbon atoms, lower alkoxy with up to and 4 carbon atoms or halogen with atomic number up to 35. 9. Compounds according to claim 6 of formula Ia, wherein R 'is hydroxymethyl, Ri' lower alkyl with up to and with 10. 5-butyryl-l, 6-dimethyl-benzimidazole-2-carboxylic acid or a salt thereof according to claim 1. 10th 11. 1,6-dimethyl-5-valeryl-benzimidazole-2-carboxylic acid or a salt thereof according to claim 1. 12. l-ethyl-5-butyryl-6-methyl-benzimidazole-2-carboxylic acid or a salt thereof according to claim 1. 13. 5-Butyryl-1,6-dimethyl-benzimidazole-2-carboxylic acid ethyl ester according to claim 1. 14. 5-butyryl-l, 6-dimethyl-benzimidazole-2-methanol according to claim 1. 15. l, 6-dimethyl-5-valeryl-benzimidazole-2-methanol according to claim 1. 15 20th 25th 30th 35 40 45 50 55 60 65 16. 1-ethyl-5-butyryl-6-methyl-benzimidazole-2-methanol according to claim 1. 17. 2-ethoxymethyl-5-butyryl-1,6-dimethyl-benzimidazole according to claim 1. 18. 2-acetoxymethyl-5-butyryl-l, 6-dimethyl-benzimidazole according to claim 1. 19. Pharmaceutical preparations containing a compound according to claim 1. 20. Pharmaceutical preparations according to claim 19, containing a compound according to one of claims 2 to 18.